

(11) EP 1 188 822 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

- (43) Date of publication: 20.03.2002 Builetin 2002/12
- (21) Application number: 00915436.0
- (22) Date of filing: 07.04.2000

- (51) Int Ci.7: **C12N 1/21**, C12N 1/32, C12N 9/00, C12N 15/52, C12P 13/04
- (86) International application number: PCT/JP00/02295
- (87) International publication number: WO 00/61723 (19.10.2000 Gazette 2000/42)
- (84) Designated Contracting States:

 AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU

 MC NL PT SE
- (30) Priority: 09.04.1999 JP 10314399 16.06.1999 JP 16944799 24.12.1999 JP 36809799
- (71) Applicant: Ajinomoto Co., Inc. Tokyo 104-0031 (JP)
- (72) Inventors:
 - GUNJI, Yoshiya, Ajinomoto Co., Inc. Kawasaki-shi, Kanagawa 210-0801 (JP)
 - YASUEDA, Hisashi, Ajinomoto Co., Inc. Kawasaki-shi, Kanagawa 210-0801 (JP)

- SUGIMOTO, Shinichi, Ajinomoto Co., Inc. Kawasaki-shi, Kanagawa 210-0801 (JP)
- TSUJIMOTO, Nobuharu, Ajinomoto Co., Inc. Kawasaki-shi, Kanagawa 210-0801 (JP)
- SHIMAOKA, Megumi, Ajinomoto Co., Inc. Kawasaki-shl, Kanagawa 210-0801 (JP)
- MIYATA, Yuri, Ajinomoto Co., Inc. Kawasaki-shi, Kanagawa 210-0801 (JP)
- OBA, Manami, Ajinomoto Co., Inc.
 Kawasaki-shi, Kanagawa 210-0801 (JP)
- (74) Representative: Strehl Schübel-Hopf & Partner Maximilianstrasse 54 80538 München (DE)

(54) L-AMINO ACID-PRODUCING BACTERIA AND PROCESS FOR PRODUCING L-AMINO ACID

(57) An L-amino acid is produced by culturing a *Methylophilus* bacterium which can grow by using methanol as a main carbon source and has L-amino acid-producing ability, for example, a *Methylophilus* bacterium in which dihydrodipicolinate synthase activity and aspartokinase activity are enhanced by transformation through introduction into cells, of a DNA coding for dihydrodipicolinate synthase that does not suffer feed-

back inhibition by L-lysine and a DNA coding for aspartokinase that does not suffer feedback inhibition by L-lysine, or a *Methylophilus* bacterium made to be casamino acid auxotrophic, in a medium containing methanol as a main carbon source, to produce and accumulate an L-amino acid in culture, and collecting the L-amino acid from the culture.

Description

TECHNICAL FIELD

⁵ [0001] The present invention relates to techniques in the field of microbial industry. In particular, the present invention relates to a method for producing an L-amino acid by fermentation, and a microorganism used in the method.

BACKGROUND ART

[0002] Amino acids such as L-lysine, L-glutamic acid, L-threonine, L-leucine, L-isoleucine, L-valine and L-phenyla-lanine are industrially produced by fermentation by using microorganisms that belong to the genus Brevibacterium, Corynebacterium, Bacillus, Escherichia, Streptomyces, Pseudomonas, Arthrobacter, Serratia, Penicillium, Candida or the like. In order to improve the productivity, strains isolated from nature or artificial mutants thereof have been used as these microorganisms. Various techniques have been disclosed for enhancing activities of L-glutamic acid biosynthetic enzymes by using recombinant DNA techniques, to increase the L-glutamic acid-producing ability.

[0003] The productivity of L-amino acids has been considerably increased by breeding of microorganisms such as those mentioned above and the improvement of production methods. However, in order to meet further increase in the demand in future, development of methods for more efficiently producing L-amino acids at lower cost have still been desired.

[0004] As methods for producing amino acids by fermentation of methanol which is a fermentation raw material available in a large amount at a low cost, there have conventionally known methods using microorganisms that belong to the genus Achromobacter or Pseudomonas (Japanese Patent Publication (Kokoku) No. 45-25273/1970), Protaminobacter (Japanese Patent Application Laid-open (Kokai) No. 49-125590/1974), Protaminobacter or Methanomonas (Japanese Patent Application Laid-open (Kokai) No. 50-25790/1975), Microcyclus (Japanese Patent Application Laid-open (Kokai) No. 52-18886/1977), Methylobacillus (Japanese Patent Application Laid-open (Kokai) No. 3-505284/1991) and so forth.

[0005] So far, however, no method has been known for producing L-amino acids by using *Methylophilus* bacteria. Although methods described in EP 0 035 831 A, EP 0 037 273 A and EP 0 066 994 A have been known as methods for transforming *Methylophilus* bacteria by using recombinant DNA, applying recombinant DNA techniques to improvement of amino acid productivity of *Methylophilus* bacteria has not been known.

DISCLOSURE OF THE INVENTION

30

35

40

45

50

[0006] The object of the present invention is to provide a novel L-amino acid-producing bacterium and a method for producing an L-amino acid by using the L-amino acid-producing bacterium.

[0007] As a result of the present inventors' efforts devoted to achieve the aforementioned object, they found that *Methylophilus* bacteria were suitable for producing L-amino acids. Further, although it has conventionally been considered difficult to obtain auxotrophic mutants of *Methylophilus* bacteria (FEMS Microbiology Rev. 39, 235-258 (1986) and Antonie van Leeuwenhoek 53, 47-53 (1987)), the present inventors have succeeded in obtaining auxotrophic mutants of said bacteria. Thus, the present invention has been accomplished.

[0008] That is, the present invention provides the followings.

- (1) A Methylophilus bacterium having L-amino acid-producing ability.
- (2) The *Methylophilus* bacterium according to (1), wherein the L-amino acid is L-lysine, L-valine, L-leucine, L-isoleucine or L-threonine.
- (3) The *Methylophilus* bacterium according to (1), which has resistance to an L-amino acid analogue or L-amino acid auxotrophy.
- (4) The Methylophilus bacterium according to (1), wherein L-amino acid biosynthetic enzyme activity is enhanced.
- (5) The *Methylophilus* bacterium according to (1), wherein dihydrodipicolinate synthase activity and aspartokinase activity are enhanced, and the bacterium has L-lysine-producing ability.
- (6) The *Methylophilus* bacterium according to (1), wherein dihydrodipicolinate synthase activity is enhanced, and the bacterium has L-lysine-producing ability.
- (7) The *Methylophilus* bacterium according to (1), wherein aspartokinase activity is enhanced, and the bacterium has L-lysine-producing ability.
- (8) The Methylophilus bacterium according to any one of (5) to (7), wherein an activity or activities of one, two or three of enzymes selected from aspartic acid semialdehyde dehydrogenase, dihydrodipicolinate reductase and diaminopimelate decarboxylase is/are enhanced.
 - (9) The Methylophilus bacterium according to (5), wherein the dihydrodipicolinate synthase activity and the aspar-

tokinase activity are enhanced by transformation through introduction into cells, of a DNA coding for dihydrodipicolinate synthase that does not suffer feedback inhibition by L-lysine and a DNA coding for aspartokinase that does not suffer feedback inhibition by L-lysine.

- (10) The bacterium according to (1), wherein activities of aspartokinase, homoserine dehydrogenase, homoserine kinase and threonine synthase, and the bacterium has L-threonine-producing ability.
- (11) The bacterium according to any one of (1) to (10), wherein the Methylophilus bacterium is Methylophilus methylotrophus.
- (12) A method for producing an L-amino acid, which comprises culturing a *Methylophilus* bacterium as defined in any one of the above (1) to (11) in a medium to produce and accumulate an L-amino acid in culture and collecting the L-amino acid from the culture.
- (13) The method according to (12), wherein the medium contains methanol as a main carbon source.
- (14) A method for producing bacterial cells of a *Methylophilus* bacterium with an increased content of an L-amino acid, which comprises culturing a *Methylophilus* bacterium as defined in any one of the above (1) to (11) in a medium to produce and accumulate an L-amino acid in bacterial cells of the bacterium.
- (15) The method for producing bacterial cells of the *Methylophilus* bacterium according to (14), wherein the L-amino acid is L-lysine, L-valine, L-leucine, L-isoleucine or L-threonine.
- (16) A DNA which codes for a protein defined in the following (A) or (B):

5

10

15

20

25

30

35

40

45

50

55

- (A) a protein which has the amino acid sequence of SEQ ID NO: 6, or
- (B) a protein which has an amino acid sequences of SEQ ID NO: 6 including substitution, deletion, insertion, addition of inversion of one or several amino acids, and has aspartokinase activity.
- (17) The DNA according to (16), which is a DNA defined in the following (a) or (b):
 - (a) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 510 to 1736 of SEQ ID NO: 5; or
 - (b) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 510 to 1736 of SEQ ID NO: 5 or a part thereof under a stringent condition, and codes for a protein having aspartokinase activity.
- (18) A DNA which codes for a protein defined in the following (C) or (D):
 - (C) a protein which has the amino acid sequence of SEQ ID NO: 8, or
 - (D) a protein which has an amino acid sequences of SEQ ID NO: 8 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has aspartic acid semialdehyde dehydrogenase activity.
- (19) The DNA according to (18), which is a DNA defined in the following (c) or (d):
- (c) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 98 to 1207 of SEQ ID NO: 7; or
 - (d) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 98 to 1207 of SEQ ID NO: 7 or a part thereof under a stringent condition, and codes for a protein having aspartic acid semialdehyde dehydrogenase activity.
 - (20) A DNA which codes for a protein defined in the following (E) or (F):
 - (E) a protein which has the amino acid sequence of SEQ ID NO: 10, or
 - (F) a protein which has an amino acid sequences of SEQ ID NO: 10 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has dihydrodipicolinate synthase activity.
 - (21) The DNA according to (20), which is a DNA defined in the following (e) or (f):
 - (e) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 1268 to 2155 of SEQ ID NO: 9; or
 - (f) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 1268 to 2155 of SEQ ID NO: 9 or a part thereof under a stringent condition, and codes for a protein having dihydrodipicolinate synthase activity.

- (22) A DNA which codes for a protein defined in the following (G) or (H):
 - (G) a protein which has the amino acid sequence of SEQ ID NO: 12, or
 - (H) a protein which has an amino acid sequences of SEQ ID NO: 12 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has dihydrodipicolinate reductase activity.
- (23) The DNA according to (22), which is a DNA defined in the following (g) or (h):
 - (g) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 2080 to 2883 of SEQ ID NO: 11; or
 - (h) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 2080 to 2883 of SEQ ID NO: 11 or a part thereof under a stringent condition, and codes for a protein having dihydrodipicolinate reductase activity.
- (24) A DNA which codes for a protein defined in the following (I) or (J):
 - (I) a protein which has the amino acid sequence of SEQ ID NO: 14, or
 - (J) a protein which has an amino acid sequences of SEQ ID NO: 14 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has diaminopimelate decarboxylase activity.
 - (25) The DNA according to (24), which is a DNA defined in the following (i) or (j):
 - (i) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 751 to 1995 of SEQ ID NO: 13; or
 - (j) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 751 to 1995 of SEQ ID NO: 13 or a part thereof under a stringent condition, and codes for a protein having diaminopimelate decarboxylase activity.
- [0009] In the present specification, "L-amino acid-producing ability" refers to ability to accumulate a significant amount of an L-amino acid in a medium or to increase the amino acid content in the microbial cells when a microorganism of the present invention is cultured in the medium.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010]

5

10

15

20

25

40

45

50

- Fig. 1 shows the production process of plasmid RSF24P having a mutant *dapA*. The "dapA*24" refers to a mutant *dapA* that codes for a mutant DDPS wherein the 118-histidine residue is replaced with a tyrosine residue.
- Fig. 2 shows the production process of plasmid RSFD80 having a mutant *dapA* and a mutant *lysC*. The "lysC*80" refers to a mutant *lysC* that codes for a mutant AKIII wherein the 352-threonine residue is replaced with an isoleucine residue.
- Fig. 3 shows aspartokinase activity of transformant E. coli strains containing an ask gene.
- Fig. 4 shows aspartic acid semialdehyde dehydrogenase activity of transformant *E. coli* strains containing an *asd* gene
- Fig. 5 shows dihydrodipicolinate synthase activity of transformant E. coli strains containing a dapA gene.
- Fig. 6 shows dihydrodipicolinate reductase activity of a transformant *E. ∞li* strain containing a *dapB* gene.
- Fig. 7 shows diaminopimelate decarboxylase activity of transformant E. coli strains containing a IysA gene.

BEST MODE FOR CARRYING OUT THE INVENTION

- <1> Microorganism of the present invention
- [0011] The microorganism of the present invention is a bacterium belonging to the genus *Methylophilus* and having L-amino acld-producing ability. The *Methylophilus* bacterium of the present invention includes, for example, *Methylophilus methylotrophus* AS1 strain (NCIMB10515) and so forth. The *Methylophilus methylotrophus* AS1 strain (NCIMB10515) is available from National Collections of Industrial and Marine Bacteria (Address: NCIMB Lts., Torry Research Station 135, Abbey Road, Aberdeen AB9 8DG, United Kingdom).
- [0012] L-Amino acids produced according to the present invention include L-lysine, L-glutamic acid, L-threonine, L-

valine, L-leucine, L-isoleucine, L-tryptophan, L-phenylalanine, L-tyrosine and so forth. One or more types of such amino acids may be produced.

[0013] Methylophilus bacteria having L-amino acid-producing ability can be obtained by imparting L-amino acid-producing ability to wild strains of Methylophilus bacteria. In order to impart L-amino acid-producing ability, there can be used methods conventionally adopted for breeding coryneform bacteria, Escherichia bacteria or the like, such as those methods for obtaining auxotrophic mutant strains, strains resistant to L-amino acid analogues or metabolic control mutant strains, and methods for producing recombinant strains wherein L-amino acid biosynthetic enzyme activities are enhanced (see "Amino Acid Fermentation", the Japan Scientific Societies Press [Gakkai Shuppan Center], 1st Edition, published on May 30, 1986, pp.77 to 100). In breeding of amino acid-producing bacteria, the characteristic such as auxotrophy, L-amino acid analogue resistance and metabolic control mutation may be imparted alone or in combination of two or more. The L-amino acid biosynthetic enzyme activity may be enhanced alone or in combination of two or more. Further, imparting of the characteristic such as auxotrophy, L-amino acid analogue resistance and metabolic control mutation may be combined with enhancement of the L-amino acid biosynthesis enzyme activity.

[0014] For example, L-lysine-producing bacteria are bred as mutants exhibiting auxotrophy for L-homoserine or L-threonine and L-methionine (Japanese Patent Publication. (Kokoku) Nos. 48-28078/1973 and 56-6499/1981), mutants exhibiting auxotrophy for inositol or acetic acid (Japanese Patent Application Laid-open (Kokai) Nos. 55-9784/1980 and 56-8692/1981), or mutants that are resistant to oxalysine, lysine hydroxamate, S-(2-aminoethyl)-cysteine, γ -methyllysine, α -chlorocaprolactam, DL- α -amino- ϵ -caprolactam, α -aminolauryllactam, aspartic acid analogue, sulfa drug, quinoid or N-lauroylleucine.

[0015] Further, L-glutamic acid-producing bacteria can be bred as mutants exhibiting auxotrophy for oleic acid or the like. L-Threonine-producing bacteria can be bred as mutants resistant to α-amino-β-hydroxyvaleric acid. L-Homoser-ine-producing bacteria can be bred as mutants exhibiting auxotrophy for L-threonine or mutants resistant to L-pheny-lalanine analogues. L-Phenylalanine-producing bacteria can be bred as mutants exhibiting auxotrophy for L-tyrosine. L-Isoleucine-producing bacteria can be bred as mutants exhibiting auxotrophy for L-leucine. L-Proline-producing bacteria can be bred as mutants exhibiting auxotrophy for L-leucine.

[0016] Furthermore, as mentioned in the examples hereinafter, strains that produce one or more kinds of branched amino acids (L-valine, L-leucine and L-isoleucine) can be obtained as strains exhibiting auxotrophy for casamino acid. [0017] In order to obtain mutants from *Methylophilus* bacteria, the inventors of the present invention first examined details of an optimal mutagenesis condition by using emergence frequency of streptomycin resistant strains as an index. As a result, the maximum emergence frequency of streptomycin resistant strains was obtained when the survival rate after mutagenesis was about 0.5%, and they succeeded in obtaining auxotrophic strains under this condition. They also succeeded in obtaining auxotrophic strains, which had been considered difficult, by largely scaling up the screening of mutants compared with that previously conducted for *E. coli* and so forth.

[0018] As described above, since it has been revealed that mutants can be obtained by mutagenizing *Methylophilus* bacteria under a suitable condition, it has become possible to readily obtain desired mutants by suitably setting such a condition that the survival rate after the mutagenesis should become about 0.5%, depending on the mutagenesis method.

[0019] Mutagenesis methods for obtaining mutants from *Methylophilus* bacteria include UV irradiation and treatments with mutagenesis agents used for usual mutatagenesis treatments such as *N*-methyl-*N*-nitro-*N*-nitrosoguanidine (NTG) and nitrous acid. *Methylophilus* bacteria having L-amino acid-producing ability can also be obtained by selecting naturally occurring mutants of *Methylophilus* bacteria.

[0020] L-Amino acid analogue-resistant mutants can be obtained by, for example, inoculating mutagenized *Methyl-ophilus* bacteria to an agar medium containing an L-amino acid analogue at a variety of concentrations and selecting strains that form colonies.

[0021] Auxotrophic mutants can be obtained by allowing *Methylophilus* bacteria to form colonies on an agar medium containing a target nutrient (for example, L-amino acid), replicating the colonies to an agar medium not containing said nutrient, and selecting strains that cannot grow on the agar medium not containing the nutrient.

[0022] Methods for imparting or enhancing L-amino acid-producing ability by enhancing L-amino acid biosynthetic enzyme activity will be exemplified below.

[L-Lysine]

10

20

30

45

50

[0023] L-Lysine-producing ability can be imparted by, for example, enhancing dihydrodipicolinate synthase activity and/or aspartokinase activity.

[0024] The dihydrodipicolinate synthase activity and/or the aspartokinase activity in *Methylophilus* bacteria can be enhanced by ligating a gene fragment coding for dihydrodipicolinate synthase and/or a gene fragment coding for aspartokinase with a vector that functions in *Methylophilus* bacteria, preferably a multiple copy type vector, to create a recombinant DNA, and introducing them into a *Methylophilus* bacterium host to transform the host. As a result of the

increase in the copy numbers of the gene coding for dihydrodipicolinate synthase and/or the gene coding for aspartokinase in cells of the transformant strain, the activity or activities thereof is/are enhanced. Hereafter, dihydrodipicolinate synthase, aspartokinase and aspartokinase III are also referred with abbreviations of DDPS, AK and AKIII, respectively.

[0025] As a microorganism providing a gene that codes for DDPS and a gene that codes for AK, any microorganisms can be used so long as they have genes enabling expression of DDPS activity and AK activity in microorganisms belonging to the genus *Methylophilus*. Such microorganisms may be wild strains or mutant strains derived therefrom. Specifically, examples of such microorganisms include *E. coli* (*Escherichia coli*) K-12 strain, *Methylophilus methylotrophus* AS1 strain (NCIMB10515) and so forth. Since nucleotide sequences of a gene coding for DDPS (*dapA*, Richaud, F. et al., J. Bacteriol., 297, (1986)) and a gene coding for AKIII (*lysC*, Cassan, M., Parsot, C., Cohen, G.N. and Patte, J.C., J. Biol. Chem., 261, 1052 (1986)) derived from *Escherichia* bacteria have been both revealed, these genes can be obtained by PCR using primers synthesized based on the nucleotide sequences of these genes and chromosome DNA of microorganism such as *E. coli* K-12 or the like as a template. As specific examples, *dapA* and *lysC* derived from *E. coli* will be explained below. However, genes used for the present invention are not limited to them.

10

20

[0026] It is preferred that DDPS and AK used for the present invention do not suffer feedback inhibition by L-lysine. It has been known that wild-type DDPS derived from *E. coli* suffers feedback inhibition by L-lysine, and that wild-type AKIII derived from *E. coli* suffers suppression and feedback inhibition by L-lysine. Therefore, *dapA* and *lysC* to be introduced into *Methylophilus* bacteria preferably code for DDPS and AKIII having a mutation that desensitizes the feedback inhibition by L-lysine. Hereafter, DDPS having a mutation that desensitizes the feedback inhibition by L-lysine is also referred to as "mutant DDPS", and DNA coding for the mutant DDPS is also referred to as "mutant *dapA*". AKIII derived from *E. coli* having a mutation that desensitizes the feedback inhibition by L-lysine is also referred to as "mutant *AKIII*", and DNA coding for the mutant AKIII is also referred to as "mutant *lysC*".

[0027] According to the present invention, DDPS and AK are not necessarily required to be a mutant. It has been known that, for example, DDPS derived from *Corynebacterium* bacteria originally does not suffer feedback inhibition by L-lysine.

[0028] A nucleotide sequence of wild-type dapA derived from E. coli is exemplified by SEQ ID NO: 1. The amino acid sequence of wild-type DDPS coded by said nucleotide sequence is exemplified by SEQ ID NO: 2. A nucleotide sequence of wild-type lysC derived from E. coli is exemplified by SEQ ID NO: 3. The amino acid sequence of wild-type ATIII coded by said nucleotide sequence is exemplified by SEQ ID NO: 4.

[0029] The DNA coding for mutant DDPS that does not suffer feedback inhibition by L-lysine includes a DNA coding for DDPS having the amino acid sequence described in SEQ ID NO: 2 wherein the 118-histidine residue is replaced with a tyrosine residue. The DNA coding for mutant AKIII that does not suffer feedback inhibition by L-lysine includes a DNA coding for AKIII having an amino sequence described in SEQ ID NO: 4 wherein the 352-threonine residue is replaced with an isoleucine residue.

[0030] The plasmid used for gene cloning may be any plasmid so long as it can replicate in microorganisms such as Escherichia bacteria or the like, and specifically include pBR322, pTWV228, pMW119, pUC19 and so forth.

[0031] The vector that functions in *Methylophilus* bacteria is, for example, a plasmid that can autonomously replicate in *Methylophilus* bacteria. Specifically, there can be mentioned RSF1010, which is a broad host spectrum vector, and derivatives thereof, for example, pAYC32 (Chistorerdov, A.Y., Tsygankov, Y.D. Plasmid, 16, 161-167, (1986)), pMFY42 (Gene, 44, 53, (1990)), pRP301, pTB70 (Nature, 287, 396, (1980)) and so forth.

[0032] In order to prepare a recombinant DNA by ligating dapA and lysC to a vector that functions in Methylophilus bacteria, the vector is digested with a restriction enzyme that corresponds to the terminus of DNA fragment containing dapA and lysC. Ligation is usually performed by using ligase such as T4 DNA ligase. dapA and lysC may be individually incorporated into separate vectors or into a single vector.

[0033] As a plasmid containing a mutant *dapA* coding for mutant DDPS and a mutant *lysC* coding for mutant AKIII, a broad host spectrum plasmid RSFD80 has been known (WO95/16042). *E. coli* JM109 strain transformed with this plasmid was designated as AJ12396, and deposited at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code 305-8566, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on October 28, 1993 and received an accession number of FERM P-13936, and it was transferred to an international deposition under the provisions of the Budapest Treaty on November 1, 1994, and received an accession number of FERM BP-4859. RSFD80 can be obtained from the AJ12396 strain in a known manner.

[0034] The mutant dapA contained in RSFD80 has a nucleotide sequence of wild-type dapA of SEQ ID NO: 1 including replacement of C at the nucleotide number 597 with T. The mutant DDPS encoded thereby has an amino acid sequence of SEQ ID NO: 2 including replacement of the 118-histidine residue with a tyrosine residue. The mutant lysC contained in RSFD80 has a nucleotide sequence of wild-type lysC of SEQ ID NO: 3 including replacement of C at the nucleotide number 1638 with T. The mutant AKIII encoded thereby has an amino acid sequence of SEQ ID NO: 4 including replacement of the 352-threonine residue with an isoleucine residue.

[0035] In order to introduce a recombinant DNA prepared as described above into *Methylophilus* bacteria, any method can be used so long as it provides sufficient transformation efficiency. For example, electroporation can be used (Canadian Journal of Microbiology, 43, 197 (1997)).

[0036] The DDPS activity and/or the AK activity can also be enhanced by the presence of multiple copies of dapA and/or lysC on chromosome DNA of Methylophilus bacteria. In order to introduce multiple copies of dapA and/or lysC into chromosome DNA of Methylophilus bacteria, homologous recombination is performed by using, as a target, a sequence that is present on chromosome DNA of Methylophilus bacteria in a multiple copy number. As the sequence present on chromosome DNA in the multiple copy number, a repetitive DNA, inverted repeats present at the end of a transposable element, or the like can be used. Alternatively, as disclosed in Japanese Patent Application Laid-open (Kokai) No. 2-109985/1990, multiple copies of dapA and/or lysC can be introduced into chromosome DNA by mounting them on a transposon to transfer them. In both of the methods, as a result of increased copy number of dapA and/or lysC in transformed strains, the DDPS activity and the AK activity should be amplified.

[0037] Besides the above gene amplification, the DDPS activity and/or the AK activity can be amplified by replacing an expression control sequence such as promoters of dapA and/or lysC with stronger ones (Japanese Patent Application Laid-open (Kokai) No. 1-215280/1989). As such strong promoters, there have been known, for example, lac promoter, trc promoter, trc promoter, trc promoter, trc promoter, trc promoter, amy E promoter, E promoter and so forth. Substitution of these promoters enhances expression of trc and trc and trc and thus the DDPS activity and the AK activity are amplified. Enhancement of expression control sequences can be combined with increase of the copy numbers of trc and/or trc trc

[0038] In order to prepare a recombinant DNA by ligating a gene fragment and a vector, the vector is digested with a restriction enzyme corresponding to the terminus of the gene fragment. Ligation is usually performed by ligase such as T4 DNA ligase. As methods for digestion, ligation and others of DNA, preparation of chromosome DNA, PCR, preparation of plasmid DNA, transformation, design of oligonucleotides used as primers and so forth, usual methods well known to those skilled in the art can be used. Such methods are described in Sambrook, J., Fritsch, E. F., and Maniatis, T., "Molecular Cloning: A Laboratory Manual, 2nd Edition", Cold Spring Harbor Laboratory Press, (1989) and so forth.

[0039] In addition to the enhancement of the DDPS activity and/or the AK activity, activity of another enzyme involved in the L-lysine biosynthesis may also be enhanced. Such enzymes include diaminopimelate pathway enzymes such as dihydrodipicolinate reductase, diaminopimelate decarboxylase, diaminopimelate dehydrogenase (WO96/40934 for all of the foregoing enzymes), phosphoenolpyruvate carboxylase (Japanese Patent Application Laid-open (Kokai) No. 60-87788/1985), aspartate aminotransferase (Japanese Patent Publication (Kokoku) No. 6-102028/1994), diaminopimelate epimerase, aspartic acid semialdehyde dehydrogenase and so forth, or aminoadipate pathway enzymes such as homoaconitate hydratase and so forth. Preferably, activity of at least one enzyme of aspartic acid semialdehyde dehydrogenase, dihydrodipicolinate reductase and diaminopimelate decarboxylase is enhanced.

[0040] Aspartokinase, aspartic acid semialdehyde dehydrogenase, dihydrodipicolinate synthase, dihydrodipicolinate reductase and diaminopimelate decarboxylase derived form *Methylophilus methylotrophus* will be described later.

[0041] Further, the microorganisms of the present invention may be decreased in activity of an enzyme that catalyzes a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway of L-lysine, or may be deficient in such an enzyme. The enzyme that catalyzes the reaction for generating the compound other than L-lysine by branching off from the biosynthetic pathway L-lysine include homoserine dehydrogenase (see WO95/23864).

[0042] The aforementioned techniques for enhancing activity of an enzyme involved in the L-lysine biosynthesis can be similarly used for other amino acids mentioned below.

45 [L-Glutamic acid]

10

20

25

30

35

40

50

[0043] L-Glutamic acid-producing ability can be imparted to *Methylophilus* bacteria by, for example, introducing a DNA that codes for any one of enzymes including glutamate dehydrogenase (Japanese Patent Application Laid-open (Kokai) 61-268185/1986), glutamine synthetase, glutamate synthase, isocitrate dehydrogenase (Japanese Patent Application Laid-open (Kokai) Nos. 62-166890/1987 and 63-214189/1988), aconitate hydratase (Japanese Patent Application Laid-open (Kokai) No. 62-294086/1987), citrate synthase (Japanese Patent Application Laid-open (Kokai) Nos. 62-201585/1987 and 63-119688/1988), phosphoenolpyruvate carboxylase (Japanese Patent Application Laid-open (Kokai) Nos. 60-87788/1985 and 62-55089/1987), pyruvate dehydrogenase, pyruvate kinase, phosphoenolpyruvate synthase, enolase, phosphoglyceromutase, phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydrogenase, triose phosphate isomerase, fructose bisphosphate aldolase, phosphofructokinase (Japanese Patent Application Laid-open (Kokai) No. 63-102692/1988), glucose phosphate isomerase, glutamine-oxoglutarate aminotransferase (WO99/07853) and so forth.

[0044] Further, the microorganisms of the present invention may be decreased in activity of an enzyme that catalyzes

a reaction for generating a compound other than L-glutamic acid by branching off from the biosynthetic pathway of L-glutamic acid, or may be deficient in such an enzyme. The enzyme that catalyzes the reaction for generating the compound other than L-glutamic acid by branching off from the biosynthetic pathway L-glutamic acid include α -ketoglutarate dehydrogenase (α KGDH), isocitrate lyase, phosphate acetyltransferase, acetate kinase, acetohydroxy acid synthase, acetolactate synthase, formate acetyltransferase, lactate dehydrogenase, glutamate decarboxylase, 1-pyrroline dehydrogenase and so forth.

[L-Threonine]

- [0045] L-Threonine-producing ability can be imparted or enhanced by, for example, enhancing activities of aspartokinase, homoserine dehydrogenase, homoserine kinase and threonine synthase. The activities of these enzymes can be enhanced by, for example, transforming *Methylophilus* bacteria using a recombinant plasmid containing a threonine operon (Japanese Patent Application Laid-open (Kokai) Nos. 55-131397/1980, 59-31691/1984 and 56-15696/1981 and Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991).
- [0046] The production ability can also be imparted or enhanced by amplifying or introducing a threonine operon having a gene coding for aspartokinase of which feedback inhibition by L-threonine is desensitized (Japanese Patent Publication (Kokoku) No. 1-29559/1989), a gene coding for homoserine dehydrogenase (Japanese Patent Application Laid-open (Kokai) No. 60-012995/1985) or a gene coding for homoserine kinase and homoserine dehydrogenase (Japanese Patent Application Laid-open (Kokai) No. 61-195695/1986).
- [0047] Further, L-threonine-producing ability can be improved by introducing a DNA coding for a mutant phosphoenolpyruvate carboxylase having a mutation for desensitizing feedback inhibition by aspartic acid.

[L-Valine]

- [0048] L-Valine-producing ability can be imparted by, for example, introducing into *Methylophilus* bacteria an L-valine biosynthesis gene whose control mechanism has been substantially desensitized. There may also be introduced a mutation that substantially desensitizes a control mechanism of an L-valine biosynthesis gene carried by a microorganism belonging to the genus *Methylophilus*.
 - [0049] Examples of the L-valine biosynthesis gene include, for example, the *ilvGMEDA* operon of *E. coli*. Threonine deaminase encoded by an *ilvA* gene catalyzes the deamination reaction converting L-threonine into 2-ketobutyric acid, which is the rate-determining step of L-isoleucine biosynthesis. Therefore, in order to attain efficient progression of the L-valine synthesis reactions, it is preferable to use an operon that does not express threonine deaminase activity. Examples of the *ilvGMEDA* operon that does not express such threonine deaminase activity include an *ilvGMEDA* operon wherein a mutation for eliminating threonine deaminase activity is introduced into *ilvA*, or *ilvA* is disrupted, and an *ilvGMED* operon wherein *ilvA* is deleted.
 - [0050] Since the *ilvGMEDA* operon suffers expression control of operon (attenuation) by L-valine and/or L-isoleucine and/or L-ieucine, the region required for the attenuation is preferably removed or mutated to desensitize the suppression of expression by L-valine.
- [0051] An ilvGMEDA operon which does not express threonine dearninase activity and in which attenuation is desensitized as described above can be obtained by subjecting a wild-type IlvGMEDA operon to a mutagenesis treatment or modifying it by means of gene recombination techniques (see WO96/06926).

[L-Leucine]

45 [0052] L-Leucine-producing ability is imparted or enhanced by, for example, introducing into a microorganism belonging to the genus Methylophilus an L-leucine biosynthesis gene whose control mechanism has been substantially desensitized, in addition to the above characteristics required for the production of L-valine. It is also possible to introduce such a mutation that the control mechanism of an L-leucine biosynthesis gene in a microorganism belonging to the genus Methylophilus should be substantially eliminated. Examples of such a gene include, for example, an leuA gene which provides an enzyme in which inhibition by L-leucine is substantially eliminated.

[L-Isoleucine]

[0053] L-Isoleucine-producing ability can be imparted by, for example, introducing a *thrABC* operon containing a *thrA* gene coding for aspartokinase I/homoserine dehydrogenase I derived from *E. coli* wherein inhibition by L-threonine has been substantially desensitized and an *ilvGMEDA* operon which contains an *ilvA* gene coding for threonine deaminase wherein inhibition by L-isoleucine is substantially desensitized and whose region required for attenuation is removed (Japanese Patent Application Laid-open (Kokai) No. 8-47397/1996).

[Other amino acids]

[0054] Biosyntheses of L-tryptophan, L-phenylalanine, L-tyrosine, L-threonine and L-isoleucine can be enhanced by increasing phosphoenolpyruvate-producing ability of *Methylophilus* bacteria (WO97/08333).

[0055] The production abilities for L-phenylalanine and L-tyrosine are improved by amplifying or introducing a desensitized chorismate mutase-prephenate dehydratase (CM-PDT) gene (Japanese Patent Application Laid-open (Kokai) Nos. 5-236947/1993 and 62-130693/1987) and a desensitized 3-deoxy-D-arabinoheptulonate-7-phosphate synthase (DS) gene (Japanese Patent Application Laid-open (Kokai) Nos. 5-236947/1993 and 61-124375/1986).

[0056] The producing ability of L-tryptophan is improved by amplifying or introducing a tryptophan operon containing a gene coding for desensitized anthranilate synthase (Japanese Patent Application Laid-open (Kokai) Nos. 57-71397/1982, 62-244382/1987 and US Patent No. 4,371,614).

[0057] In the present specification, the expression that enzyme "activity is enhanced" usually refers to that the intracellular activity of the enzyme is higher than that of a wild type strain, and when a strain in which the activity of the enzyme is enhanced is obtained by modification using gene recombinant techniques or the like, the intracellular activity of the enzyme is higher than that of the strain before the modification. The expression that enzyme "activity is decreased" usually refers to that the intracellular activity of the enzyme is lower than that of a wild type strain, and when a strain in which the activity of the enzyme is decreased is obtained by modification using gene recombinant techniques or the like, the intracellular activity of the enzyme is lower than that of the strain before the modification.

[0058] L-Amino acids can be produced by culturing *Methylophilus* bacteria having L-amino acid-producing ability obtained as described above in a medium to produce and accumulate L-amino acids in the culture, and collecting the L-amino acids from the culture.

[0059] Bacterial cells of *Methylophilus* bacteria with an increased L-amino acid content compared with wild strains of *Methylophilus* bacteria can be produced by culturing *Methylophilus* bacteria having L-amino acid-producing ability in a medium to produce and accumulate L-amino acids in bacterial cells of the bacteria.

[0060] Microorganisms used for the present invention can be cultured by methods usually used for culturing microorganisms having methanol-assimilating property. The medium used for the present invention may be a natural or synthetic medium so long as it contains a carbon source, a nitrogen source, inorganic ions and other trace amount organic constituents as required.

[0061] By using methanol as a main carbon source, L-amino acids can be prepared at a low cost. When methanol is used as a main carbon source, it is usually added to a medium in an amount of 0.001 to 30%. As the nitrogen source, ammonium sulfate or the like is used by adding it to the medium. Other than these, there are usually added small amounts of the trace amount constituents such as potassium phosphate, sodium phosphate, magnesium sulfate, ferrous sulfate and manganese sulfate.

[0062] The culture is usually performed under an aerobic condition obtained by, for example, shaking or stirring for aeration, at pH 5 to 9 and a temperature of 20 to 45°C, and it is usually completed within 24 to 120 hours.

[0063] Collection of L-amino acids from culture can be usually attained by a combination of known methods such as those using ion exchange resin, precipitation and others.

[0064] Further, *Methylophilus* bacterium cells can be separated from the medium by usual methods for separating microbial cells.

<2> Gene of the present invention

40

[0065] The DNA of the present invention is a gene which codes for one of the enzymes, aspartokinase (henceforth also abbrevlated as "AK"), aspartic acid semialdehyde dehydrogenase (henceforth also abbrevlated as "ASD"), dihydrodipicolinate synthase (henceforth also abbrevlated as "DDPS"), dihydrodipicolinate reductase (henceforth also abbrevlated as "DDPR"), and diaminopimelate decarboxylase (henceforth also abbrevlated as "DPDC") derived from Methylophilus methylotrophus.

[0066] The DNA of the present invention can be obtained by, for example, transforming a mutant strain of a microorganism deficient in AK, ASD, DDPS, DDPR or DPDC using a gene library of *Methylophilus methylotrophus*, and selecting a clone in which auxotrophy is recovered.

[0067] A gene library of *Methylophilus methylotrophus* can be produced as follows, for example. First, total chromosome DNA is prepared from a *Methylophilus methylotrophus* wild strain, for example, the *Methylophilus methylotrophus* AS1 strain (NCIMB10515), by the method of Saito et al. (Saito, H. and Miura, K., Biochem. Biophys. Acta 72, 619-629, (1963)) or the like, and partially digested with a suitable restriction enzyme, for example, *Sau*3Al or *Alut*, to obtain a mixture of various fragments. By controlling the degree of the digestion through adjustment of digestion reaction time and so forth, a wide range of restriction enzymes can be used.

[0068] Subsequently, the digested chromosome DNA fragments are ligated to vector DNA autonomously replicable in *Escherichia coli* cells to produce recombinant DNA. Specifically, a restriction enzyme producing the same terminal

nucleotide sequence as that produced by the restriction enzyme used for the digestion of chromosome DNA is allowed to act on the vector DNA to fully digest and cleave the vector. Then, the mixture of chromosome DNA fragments and the digested and cleaved vector DNA are mixed, and a ligase, preferably T4 DNA ligase, is allowed to act on the mixture to obtain recombinant DNA.

[0069] A gene library solution can be obtained by transforming Escherichia coli, for example, the Escherichia coli JM109 strain or the like, using the obtained recombinant DNA, and preparing recombinant DNA from the culture broth of the transformant. This transformation can be performed by the method of D.M. Morrison (Methods in Enzymology 68, 326 (1979)), the method of treating recipient cells with calcium chloride so as to increase the permeability of DNA (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1970)) and so forth. In the examples mentioned hereinafter, electroporation was used.

[0070] As examples of the aforementioned vector, there can be mentioned pUC19, pUC18, pUC118, pUC119, pBR322, pHSG299, pHSG399, pHSG399, pHSG398, RSF1010, pMW119, pMW118, pMW219, pMW218, pSTV28, pSTV29 and so forth. Phage vectors can also be used. Since pUC118 and pUC119 contain an ampicillin resistance gene, and pSTV28 and pSTV29 contain a chloramphenicol resistance gene, for example, only transformants which harbor a vector or a recombinant DNA can be grown by using a medium containing ampicillin or chloramphenicol.

[0071] As the method for culturing the transformants and collecting recombinant DNA from bacterial cells, the alkali SDS method and the like can be mentioned.

[0072] A mutant microbial strain deficient in AK, ASD, DDPS, DDPS or DPDC is transformed by using the gene library solution of *Methylophilus methylotrophus* obtained as described above, and clones whose auxotrophy is recovered are selected.

[0073] Examples of a mutant microbial strain deficient in AK include *E. coli* GT3 deficient in three kinds of genes coding for AK (*thrA*, *metLM*, *lysC*). Examples of a mutant microbial strain deficient in ASD include *E. coli* Hfr3000 U482 (CGSC 5081 strain). Examples of a mutant microbial strain deficient in DDPS include *E. coli* AT997 (CGSC 4547 strain). Examples of a mutant microbial strain deficient in DDPR Include *E. coli* AT999 (CGSC 4549 strain). Examples of a mutant microbial strain deficient in DPDC include *E. coli* AT2453 (CGSC 4505 strain). These mutant strains can be obtained from *E. coli* Genetic Stock Center (the Yale University, Department of Biology, Osborn Memorial Labs., P.O. Box 6666, New Haven 06511-7444, Connecticut, U.S.).

[0074] Although all of the aforementioned mutant strains cannot grow in M9 minimal medium, transformant strains which contain a gene coding for AK, ASD, DDPS, DDPR or DPDC can grow in M9 minimal medium because these genes function in the transformants. Therefore, by selecting transformant strains that can grow in the minimal medium and collecting recombinant DNA from the strains, DNA fragments containing a gene that codes for each enzyme can be obtained. *E. coli* AT999 (CGSC 4549 strain) shows extremely slow growth rate even in a complete medium such as L medium when diaminopimelic acid is not added to the medium. However, normal growth can be observed for its transformant strains which contain a gene coding for DDPR derived from *Methylophilus methylotrophus*, because of the function of the gene. Therefore, a transformant strain that contains a gene coding for DDPR can also be obtained by selecting a transformant strain normally grown in L medium.

[0075] By extracting an insert DNA fragment from the obtained recombinant DNA and determining its nucleotide sequence, an amino acid sequence of each enzyme and nucleotide sequence of the gene coding for it can be determined.

[0076] The gene coding for AK of the present invention (henceforth also referred to "ask") codes for AK which has the amino acid sequence of SEQ ID NO: 6 shown in Sequence Listing. As a specific example of the ask gene, there can be mentioned a DNA having the nucleotide sequence which consists of nucleotides of SEQ ID NO: 5. The ask gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 6.

[0077] The gene which codes for ASD of the present invention (henceforth also referred to as "asd") codes for ASD which has the amino acid sequence of SEQ ID NO: 8 shown in Sequence Listing. As a specific example of the asd gene, a DNA which contains the nucleotide sequence consisting of the nucleotides of the nucleotide numbers 98-1207 in SEQ ID NO: 7 can be mentioned. The asd gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 8.

[0078] The gene which codes for DDPS of the present invention (henceforth also referred to as "dapA") codes for DDPS which has the amino acid sequence of SEQ ID NO: 10 shown in Sequence Listing. As a specific example of the dapA gene, a DNA which has the nucleotide sequence consisting of the nucleotides of the nucleotide numbers 1268-2155 in SEQ ID NO: 9 can be mentioned. The dapA gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 10.

[0079] The gene which codes for DDBR of the present invention (henceforth also referred to as "dapB") codes for

DDBR which has the amino acid sequence of SEQ ID NO: 12 shown in Sequence Listing. As a specific example of the *dapB* gene, a DNA which has the nucleotide sequence consisting of the nucleotides of the nucleotide numbers 2080-2883 in SEQ ID NO: 11 can be mentioned. The *dapB* gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 12.

[0080] The gene which codes for DPDC of the present invention (henceforth also referred to as "IysA") codes for DPDC which has the amino acid sequence of SEQ ID NO: 14 shown in Sequence Listing. As a specific example of the IysA gene, a DNA which has the nucleotide sequence consisting of the nucleotides of the nucleotide numbers 751-1995 in SEQ ID NO: 13 can be mentioned. The IysA gene of the present invention may have a sequence in which codon corresponding to each of the amino acids is replaced with equivalent codon so long as it codes for the same amino acid sequence as the amino acid sequence of SEQ ID NO: 14.

[0081] The gene for each enzyme of the present invention may have an amino acid sequence corresponding to each amino acid sequence of SEQ ID NO: 6, 8, 10, 12 or 14 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and may code a protein having activity of AK, ASD, DDPS, DDPR or DPDC. The expression "one or several" used herein preferably means a number of 1 to 10, more preferably a number of 1 to 5, more preferably a number of 1 to 2.

[0082] The DNA which codes for the substantially same protein as AK, ASD, DDPS, DDPR or DPDC such as those mentioned above can be obtained by modifying each nucleotide sequence so that the amino acid sequence should contain substitution, deletion, insertion, addition or inversion of an amino acid residue or residues at a particular site by, for example, site-specific mutagenesis. Such a modified DNA as mentioned above may also be obtained by a conventional mutagenesis treatment. Examples of the mutagenesis treatment include in vitro treatment of DNA coding for AK, ASD, DDPS, DDPR or DPDC with hydroxylamine or the like, treatment of a microorganism such as *Escherichia* bacteria containing a gene coding for AK, ASD, DDPS, DDPR or DPDC by UV irradiation or with mutagenesis agents used for usual mutagenesis treatment such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) and nitrous acid.

[0083] The aforementioned substitution, deletion, insertion, addition or inversion of nucleotides includes naturally occurring mutations (mutant or variant) such as those observed depending difference between species or strains of microorganisms containing AK, ASD, DDPS, DDPR or DPDC and so forth.

[0084] The DNA which codes for substantially the same protein as AK, ASD, DDPS, DDPR or DPDC can be obtained by allowing expression of a DNA having such a mutation as mentioned above in a suitable cell, and examining AK, ASD, DDPS, DDPR or DPDC activity of the expression product. The DNA which codes for substantially the same protein as AK, ASD, DDPS, DDPR or DPDC can also be obtained by isolating, from DNAs coding for AK, ASD, DDPS, DDPR or DPDC which have mutations or cells containing each of them, a DNA hybridizable with a probe containing a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 510-1736 of SEQ ID NO: 5, a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 98-1207 of SEQ ID NO: 7, a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 1268-2155 of SEQ ID NO: 9, a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 2080-2883 of SEQ ID NO: 11, or a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 751-1995 of SEQ ID NO: 13, or a part of those nucleotide sequences under a stringent condition, and coding for a protein having AK, ASD, DDPS, DDPR or DPDC activity. In the present specification, to have a nucleotide sequence or a part thereof means to have the nucleotide sequence or the part thereof, or a nucleotide complementary thereto.

[0085] The term "stringent condition" used herein means a condition that allows formation of so-called specific hybrid and does not allow formation of non-specific hybrid. This condition may vary depending on the nucleotide sequence and length of the probe. However, it may be, for example, a condition that allows hybridization of highly homologous DNA such as DNA having homology of 40% or higher, but does not allow hybridization of DNA of lower homology than defined above, or a condition that allows hybridization under a washing condition of usual Southern hybridization, of a temperature of 60°C and salt concentrations corresponding to 1 x SSC and 0.1% SDS, preferably 0.1 x SSC and 0.1% SDS.

[0086] A partial sequence of each gene can also be used as the probe. Such a probe can be produced by PCR (polymerase chain reaction) using oligonucleotides produced based on a nucleotide sequence of each gene as primers and a DNA fragment containing each gene as a template. When a DNA fragment having a length of about 300 bp is used as the probe, washing condition for hybridization may be, for example, 50°C, 2 x SSC and 0.1% SDS.

[0087] Genes that hybridize under such a condition as mentioned above also include those having a stop codon occurring in its sequence and those encoding an enzyme no longer having its activity due to a mutation of active center. However, such genes can readily be eliminated by ligating the genes to a commercially available activity expression vector, and measuring AK, ASD, DDPS, DDPR or DPDC activity.

[0088] Since the nucleotide sequences of the genes that codes for AK, ASD, DDPS, DDPR and DPDC derived from *Methylophilus methylotrophus* were revealed by the present invention, DNA sequences which code for AK, ASD, DDPS, DDPR and DPDC can be obtained from a *Methylophilus methylotrophus* gene library by hybridization using oligonu-

cleotide probes produced based on the sequences. Moreover, DNA sequences which code for these enzymes can also be obtained by amplifying them from *Methylophilus methylotrophus* chromosome DNA by PCR using oligonucleotide primers produced based on the aforementioned nucleotide sequences.

[0089] The aforementioned genes can sultably be utilized to enhance L-lysine-producing ability of *Methylophilus* bacteria.

EXAMPLES

[0090] The present invention will further specifically be explained with reference to the following examples hereafter.
[0091] The reagents used were obtained from Wako Pure Chemicals or Nakarai Tesque unless otherwise indicated.
The compositions of the media used in each example are shown below. pH was adjusted with NaOH or HCl for all media.

(L medium)	
Bacto trypton (DIFCO)	10 g/L
Yeast extract (DIFCO)	5 g/L
NaCl	5 g/L
[steam-sterilized at 120°C for	20 minutes]

(L agar medium)	
L medium	
Bacto agar (DIFCO)	15 g/L
[steam-sterilized at 120°C for	20 minutes]

(SOC medium)	
Bacto trypton (DIFCO)	20 g/L
Yeast extract (DIFCO)	5 g/L
10 mM NaCI	
2.5 mM KCI	
10 mM MgSO₄	
10 mM MgCl ₂	
20 mM Glucose	,

[The constituents except for magnesium solution and glucose were steam-sterilized (120°C, 20 minutes), then 2 M magnesium stock solution (1 M MgSO₄, 1 M MgCl₂) and 2 M glucose solution, which solutions had been passed through a 0.22-µm filter, were added thereto, and the mixture was passed through a 0.22-µm filter again.]

(121M1 medium)	
K ₂ HPO ₄	1.2 g/L
KH ₂ PO ₄	0.62 g/L
NaCl	0.1 g/L
(NH ₄) ₂ SO ₄	0.5 g/L
MgSO ₄ •7H ₂ O	0.2 g/L
CaCl ₂ •6H ₂ O	0.05 g/L
FeCl ₃ •6H ₂ O	1.0 mg/L
H ₃ BO ₃	10 μg/L
CuSO ₄ •5H ₂ O	5 μg/L
MnSO ₄ •5H ₂ O	10 μg/L
ZnSO ₄ •7H ₂ O	70 μg/L
NaMoO ₄ •2H ₂ O	10 μg/L

(continued)

(121M1 medium)	
CoCl ₂ •6H ₂ O	5 μg/L
Methanol 1% (vol/vol), pH	7.0

[The constituents except for methanol were steam-sterilized at 121°C for 15 minutes. After the constituents sufficiently cooled, methanol was added.]

(Composition of 121 production medium)		
Methanol	2%	
Dipotassium phosphate	0.12%	
Potassium phosphate	0.062%	
Calcium chloride hexahydrate	0.005%	
Magnesium sulfate heptahydrate	0.02%	
Sodium chloride	0.01%	
Ferric chloride hexahydrate	1.0 mg/L	
Ammonium sulfate	0.3%	
Cupric sulfate pentahydrate	5 μg/L	
Manganous sulfate pentahydrate	10 μg/L	
Sodium molybdate dihydrate	10 μg/L	
Boric acid	10 μg/L	
Zinc sulfate heptahydrate	70 μg/L	
Cobaltous chloride hexahydrate	5 μg/L	
Calcium carbonate (Kanto Kagaku)	3%	
(pH 7.0)		

(121M1 Agar medium)	
121M1 medium	
Bacto agar (DIFCO)	15 g/L

[The constituents except for methanol were steam-sterilized at 121°C for 15 minutes. After the constituents sufficiently cooled, methanol was added.]

(M9 minimal medium)	
Na ₂ HPO ₄ •12H ₂ O	16 g/L
KH ₂ PO ₄	3 g/L
NaCl	0.5 g/L
NH₄CI	1 g/L
MgSO ₄ •7H ₂ O	246.48 mg/L
Glucose	2 g/L
pH 7.0	

[MgSO₄ and glucose were separately sterilized (120 $^{\circ}$ C, 20 minutes) and added. A suitable amount of amino acids and vitamins were added as required.]

(M9 minimal agar medium)	
M9 minimal medium	
Bacto agar (DIFCO)	15 g/L

Example 1

20

40

Creation of L-lysine-producing bacterium (1)

5 (1) Introduction of mutant lysC and mutant dapA into Methylophilus bacterium

[0092] A mutant *lysC* and a mutant *dapA* were introduced into a *Methylophilus* bacterium by using a known plasmid RSFD80 (see WO95/16042) containing them. RSFD80 is a plasmid pVIC40 (International Publication WO90/04636, Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991) derived from a broad host spectrum vector plasmid pAYC32 (Chistorerdov, A.Y., Tsygankov, Y.D., Plasmid, 16, 161-167, (1986)), which is a derivative of RSF1010, in which a mutant *dapA* and a mutant *lysC* derived from *E. coli* are located in this order downstream of the promoter (tetP) of the tetracycline resistance gene of pVIC40 so that the transcription directions of the genes are ordinary with respect to tetP. The mutant *dapA* coded for a mutant DDPS in which the 118-histidine residue was replaced with an Isoleucine residue. The mutant *lysC* coded for a mutant AKIII in which the 352-threonine residue was replaced with an Isoleucine residue.

[0093] RSFD80 was constructed as follows. The mutant dapA on a plasmid pdapAS24 was ligated to pVIC40 at a position downstream of the promoter of the tetracycline resistance gene to obtain RSF24P as shown in Fig. 1. Then, the plasmid RSFD80 which had the mutant dapA and a mutant lysC was prepared from RSF24P and pLLC*80 containing the mutant lysC as shown in Fig. 2. That is, while pVIC40 contains a threonine operon, this threonine operon is replaced with a DNA fragment containing the mutant dapA and a DNA fragment containing the mutant lysC in RSFD80.

[0094] The *E. coli* JM109 strain transformed with the RSFD80 plasmid was designated as AJ12396, and deposited at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code 305-8566, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on October 28, 1993 and received an accession number of FERM P-13936, and it was transferred to an international deposition under the provisions of the Budapest Treaty on November 1, 1994, and received an accession number of FERM BP-4859.

[0095] The *E. coli* AJ1239 strain was cultured in 30 ml of LB medium containing 20 mg/L of streptomycin at 30°C for 12 hours, and the RSFD80 plasmid was purified from the obtained cells by using Wizard® Plus Midipreps DNA Purification System (sold by Promega).

[0096] The RSFD80 plasmid produced as described above was introduced into the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) by electroporation (Canadian Journal of Microbiology, 43, 197 (1997)). As a control, a DNA region coding for the threonine operon was deleted from the pVIC40 plasmid used for producing the RSFD80 plasmid to produce a pRS plasmid comprising only the vector region (see Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991), and the pRS plasmid was introduced into the AS1 strain in the same manner as that used for RSFD80.

(2) AKIII Activity of Methylophilus bacterium containing mutant lysC and mutant dapA derived from E. coli

[0097] Cell-free extracts were prepared from the *Methylophilus methylotrophus* AS1 strain containing the RSFD80 plasmid (also referred to as "AS1/RSFD80" hereinafter) and the *Methylophilus methylotrophus* AS1 strain containing the pRS plasmid (also referred to as "AS1/pRS" hereinafter), and AK activity was measured. The cell-free extracts (crude enzyme solutions) were prepared as follows. The AS1/RSFD80 strain and AS1/pRS strain were each inoculated to 121 production medium of the above composition containing 20 mg/L of streptomycin, cultured at 37°C for 34 hours with shaking, and then calcium carbonate was removed and cells were harvested.

[0098] The bacterial cells obtained as described above were washed with 0.2% KCl under a condition of 0°C, suspended in 20 mM potassium phosphate buffer (pH 7) containing 10 mM MgSO₄, 0.8 M (NH₄)₂SO₄ and 0.03 M β -mercaptoethanol, and disrupted by sonication (0°C, 200 W, 10 minutes). The sonicated cell suspension was centrifuged at 33,000 rpm for 30 minutes under a condition of 0°C, and the supernatant was separated. To the supernatant, ammonium sulfate was added to 80% saturation, and the mixture was left at 0°C for 1 hour, and centrifuged. The pellet was dissolved in 20 mM potassium phosphate buffer (pH 7) containing 10 mM MgSO₄, 0.8 M (NH₄)₂SO₄ and 0.03 M β -mercaptoethanol.

[0099] The measurement of AK activity was performed in accordance with the method of Stadtman (Stadtman, E. R., Cohen, G.N., LeBras, G., and Robichon-Szulmajster, H., J. Biol. Chem., 236, 2033 (1961)). That is, a reaction solution of the following composition was incubated at 30°C for 45 minutes, and color development was caused by adding a FeCl₃ solution (2.8 N HCl: 0.4 ml, 12% TCA: 0.4 ml, 5% FeCl₃•6H₂O/0.1 N HCl: 0.7 ml). The reaction solution was centrifuged, and absorbance of the supernatant was measured at 540 nm. The activity was represented in terms of the amount of hydroxamic acid produced in 1 minute (1 U = 1 μ mol/minute). The molar extinction coefficient was set to be 600. The reaction solution not containing potassium aspartate was used as a blank. When the enzymatic

activity was measured, L-lysine was added to the enzymatic reaction solution at various concentrations to examine degree of inhibition by L-lysine. The results are shown in Table 1.

(Composition of reaction solution)	
Reaction mixture *1	0.3 ml
Hydroxylamine solution ¹²	0.2 ml
0.1 M Potassium aspartate (pH 7.0)	0.2 ml
Enzyme solution	0.1 ml
Water (balance)	Total 1 ml

^{*1: 1} M Tris-HCl (pH 8.1): 9 ml, 0.3 M MgSO₄: 0.5 ml and 0.2 M ATP (pH 7.0): 5 ml

Т

Table 1

Strain	AK activity (Specific activity*1)	Specific activity with 5 mM L- lysine	Desensitization degree of inhibition*2 (%)
AS1/pRS	7.93	9.07	114
AS1/RSFD80	13.36	15.33	115

^{*1:} nmol/minute/mg protein

5

10

15

20

25

30

40

45

[0100] As shown in Table 1, AK activity was increased by about 1.7 times by the introduction of the RSFD80 plasmid. Further, it was confirmed that the inhibition by L-lysine was completely desensitized in AK derived from E. *coli* that was encoded by the RSFD80 plasmid. Moreover, it was found that AK that was originally retained by the AS1 strain was not inhibited by L-lysine alone. The inventors of the present invention have discovered that the AK derived from the AS1 strain was inhibited by 100% when 2 mM for each of L-lysine and L-threonine were present in the reaction solution (concerted inhibition).

(3) Production of L-lysine by Methylophilus bacterium containing mutant lysC and mutant dapA derived from E. coli

[0101] Then, the AS1/RSFD80 strain and the AS1/pRS strain were inoculated to 121 production medium containing 20 mg/L of streptomycin, and cultured at 37°C for 34 hours with shaking. After the culture was completed, the bacterial cells and calcium carbonate were removed by centrifugation, and L-lysine concentration in the culture supernatant was measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). The results are shown in Table 2.

Table 2

Strain	Production amount of L-lysine hydrochloride (g/L)
AS1/pRS	0
AS1/RSFD80	0.3

Example 2

Creation of L-lysine-producing bacterium (2)

50 (1) Introduction of tac promoter region into broad host spectrum vector

[0102] In order to produce a large amount of enzyme involved in the biosynthesis of L-lysine (Lys) in *Methylophilus methylotrophus, tac* promoter was used for gene expression of the target enzyme. The promoter is frequently used in *E. coli.*

[0103] The tac promoter region was obtained by amplification through PCR using DNA of pKK233-3 (Pharmacia) as a template, DNA fragments having the nucleotide sequences of SEQ ID NOS: 15 and 16 as primers, and a heat-resistant DNA polymerase. The PCR was performed with a cycle of 94°C for 20 seconds, 60°C for 30 seconds, and 72°C for 60 seconds, which was repeated 30 times. Then, the amplified DNA fragment was collected and treated with

^{*2: 8} M Hydroxylamine solution neutralized with KOH immediately before use

^{*2:} Activity retention ratio in the presence of 5 mM LERR-lysine

restriction enzymes *EcoRI* and *Psti*. On the other hand, a broad host spectrum vector pRS (see Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991) was also digested with the same restriction enzymes, and the aforementioned DNA fragment which contained the *tac* promoter region was introduced into the restriction enzyme digestion termini to construct pRS-tac.

(2) Preparation of *dapA* gene (dihydrodipicolinate synthase gene) expression plasmid pRS-dapA24 and *lysC* gene (aspartokinase gene) expression plasmid pRS-lysC80

[0104] A mutant gene (dapA*24) coding for dihydrodipicolinate synthase whose feedback inhibition for the enzyme activity by Lys was partially desensitized was introduced into the plasmid pRS-tac which was prepared by the method described in the above (1).

[0105] First, the dapA*24 gene region was obtained by amplification through PCR using DNA of RSFD80 (see Example 1) as a template, and DNA fragments having the nucleotide sequences of SEQ ID NOS: 17 and 18 as primers. The PCR was performed with a cycle of 94°C for 20 seconds, 60°C for 30 seconds, and 72°C for 90 seconds, which was repeated 30 times. Then, the fragment was treated with restriction enzymes Sse8387I and XbaI to prepare a dapA*24 gene fragment having corresponding cleaved termini. On the other hand, pRS-tac was also treated with Sse8387I and partially digested with XbaI in the same manner as described above. To this digested plasmid, the aforementioned dapA*24 gene fragment was ligated by using T4 ligase to obtain pRS-dapA24.

[0106] Similarly, a gene (*lysC*80*) coding for aspartokinase whose feedback inhibition for the enzyme activity by Lys was partially desensitized was obtained by PCR using DNA of RSFD80 as a template, and DNA fragments having the nucleotide sequences of SEQ ID NOS: 19 and 20 as primers. The PCR was performed with a cycle of 94°C for 20 seconds, 60°C for 30 seconds, and 72°C for 90 seconds, which was repeated 30 times. Then, the obtained DNA fragment was treated with restriction enzymes *Sse*8387I and *Sap*I. On the other hand, the vector pRS-tac was also treated with *Sse*8387I and *Sap*I. To this digested plasmid, the aforementioned *lysC*80* gene fragment was ligated by using T4 ligase to obtain pRS-lysC80.

(3) Introduction of pRS-dapA24 or pRS-lysC80 into Methylophilus methylotrophus and evaluation of culture

[0107] Each of pRS-dapA24 and pRS-lysC80 obtained as described above was introduced into the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) by electroporation to obtain AS1/pRS-dapA24 and AS1/pRS-lysC80, respectively. Each strain was inoculated to 121 production medium containing 20 mg/L of streptomycin, and cultured at 37°C for 48 hours with shaking. As a control strain, AS1 strain harboring pRS was also cultured in a similar manner. After the culture was completed, the cells and calcium corbonate were removed by centrifugation, and L-lysine concentration in the culture supernatant was measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). The results are shown in Table 3.

Table 3

Strain	Production amount of L-lysine hydrochloride (g/L)
AS1/pRS	<0.01
AS1/pRS-lysC80	0.06
AS1/pRS-dapA24	0.13

45 Example 3

25

35

40

Creation of L-lysine-producing bacterium (3)

[0108] The Methylophilus methylotrophus AS1 strain (NCIMB10515) was inoculated to 121M1 medium and cultured at 37°C for 15 hours. The obtained bacterial cells were treated with NTG in a conventional manner (NTG concentration: 100 mg/L, 37°C, 5 minutes), and spread onto 121M1 agar medium containing 7 g/L of S-(2-aminoethyl)-cysteine (AEC) and 3 g/L of L-threonine. The cells were cultured at 37°C for 2 to 8 days, and the formed colonies were picked up to obtain AEC-resistant strains.

[0109] The aforementioned AEC-resistant strains were inoculated to 121 production medium, and cultured at 37°C for 38 hours under an aerobic condition. After the culture was completed, the cells and calcium carbonate were removed from the medium by centrifugation, and L-lysine concentration in the culture supernatant was measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). A strain showing improved L-lysine-producing ability compared with the parent strain was selected, and designated as Methylophilus meth-

ylotrophus AR-166 strain. The L-lysine production amounts of the parent strain (AS1 strain) and the AR-166 strain are shown in Table 4.

Table 4

Strain	Production amount of L-lysine hydrochloride (mg/L)
AS1	5.8
AR-166	80

[0110] The Methylophilus methylotrophus AR-166 strain was given a private number of AJ13608, and was deposited at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code 305-8566, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on June 10, 1999 and received an accession number of FERM P-17416, and it was transferred to an international deposition under the provisions of the Budapest Treaty on March 31, 2000, and received an accession number of FERM BP-7112.

Example 4

20

Creation of L-threonine-producing bacterium

(1) Introduction of threonine operon plasmid into Methylophilus bacterium

[0111] A plasmid pVIC40 (International Publication WO90/04636, Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991) containing a threonine operon derived from *E. coli* was introduced into the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) by electroporation (Canadian Journal of Microbiology, 43, 197 (1997)) to obtain AS1/pVIC40 strain. As a control, pRS (Japanese Patent Application Laid-open (Kohyo) No. 3-501682/1991) having only the vector region was obtained by deleting the DNA region coding for the threonine operon from the pVIC40 plasmid, and it was introduced into the AS1 strain in the same manner as used for pVIC40 to obtain AS1/pRS strain.

(2) Production of L-threonine by Methylophilus bacterium containing threonine operon derived from E. coli

[0112] Each of the AS1/pVIC40 and AS1/pRS strains was inoculated to 121 production medium containing 20 mg/L of streptomycin, 1 g/l of L-valine and 1 g/l of L-leucine, and cultured at 37°C for 50 hours with shaking. After the culture was completed, the cells and calcium carbonate were removed by centrifugation, and L-threonine concentration in the culture supernatant was measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). The results are shown in Table 5.

Table 5

Strain	Production amount of L-threonine (mg/L)
AS1/pRS	15
AS1/pVIC40	30

Example 5

40

Creation of branched chain amino acid-producing bacterium

[0113] The Methylophilus methylotrophus AS1 strain (NCIMB10515) was inoculated to 121M1 medium and cultured at 37°C for 15 hours. The obtained bacterial cells were treated with NTG in a conventional manner (NTG concentration: 100 mg/L, 37°C, 5 minutes), and spread onto 121M1 agar medium containing 0.5% of casamino acid (DIFCO). The cells were cultured at 37°C for 2 to 8 days, and allowed to form colonies. The formed colonies were picked up, and inoculated to 121M1 agar medium and 121M1 agar medium containing 0.5% of casamino acid. Strains exhibiting better growth on the latter medium compared with on the former medium were selected as casamino acid auxotrophic strains. In this way, 9 leaky casamino acid auxotrophic strains were obtained from NTG-treated 500 strains. From these casamino acid auxotrophic strains, one strain that accumulated more L-valine, L-leucine and L-isoleucine in the medium compared with its parent strain was obtained. This strain was designated as Methylophilus methylotrophus C138 strain. [0114] The Methylophilus methylotrophus C138 strain was given a private number of AJ13609, and was deposited

at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code 305-8566, 1-3 Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on June 10, 1999 and received an accession number of FERM P-17417, and it was transferred to an international deposition under the provisions of the Budapest Treaty on March 31, 2000, and received an accession number of FERM BP-7113.

[0115] The parent strain (AS1 strain) and the C138 strain were inoculated to 121 production medium, and cultured at 37°C for 34 hours under an aerobic condition. After the culture was completed, the cells and calcium carbonate were removed from the medium by centrifugation, and concentrations of L-valine, L-leucine and L-isoleucine in the culture supernatant were measured by an amino acid analyzer (JASCO Corporation [Nihon Bunko], high performance liquid chromatography). The results are shown in Table 6.

Table 6

Strain	L-valine (mg/L)	L-leucine (mg/L)	L-isoleucine (mg/L)
AS1	7.5	5.0	2.7
C138	330	166	249

Example 6

10

15

20

40

Preparation of chromosome DNA library of Methylophilus methylotrophus AS1 strain

(1) Preparation of chromosome DNA of Methylophilus methylotrophus AS1 strain

[0116] One platinum loop of the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) was inoculated to 5 ml of 121M1 medium in a test tube, and cultured at 37°C overnight with shaking. The obtained culture broth was inoculated to 50 ml of 121M1 medium in a 500 ml-volume Sakaguchi flask in an amount of 1%, and cultured at 37°C overnight with shaking. Then, the cells were harvested by centrifugation, and suspended in 50 ml of TEN solution (solution containing 50 mM Tris-HCl (pH 8.0), 10 mM EDTA and 20 mM NaCl (pH 8.0)). The cells were collected by centrifugation, and suspended again in 5 ml of the TEN solution containing 5 mg/ml of lysozyme and 10 µg/ml of RNase A. The suspension was maintained at 37°C for 30 minutes, and then proteinase K and sodium laury/sulfate were added thereto to final concentrations of 10 µg/ml and 0.5% (wt/vol), respectively.

[0117] The suspension was maintained at 70°C for 2 hours, and then an equal amount of a saturated solution of phenol (phenol solution saturated with 10 mM Tris-HCI (pH 8.0)) was added and mixed. The suspension was centrifuged, and the supernatant was collected. An equal amount of phenol/chloroform solution (phenol:chloroform:isoamyl alcohol = 25:24:1) was added and mixed, and the mixture was centrifuged. The supernatant was collected, and an equal amount of chloroform solution (chloroform:isoamyl alcohol = 24:1) was added thereto to repeat the same extraction procedure. To the supernatant, a 1/10 volume of 3 M sodium acetate (pH 4.8) and 2.5-fold volume of ethanol were added to precipitate chromosome DNA. The precipitates were collected by centrifugation, washed with 70% ethanol, dried under reduced pressure, and dissolved in a suitable amount of TE solution (10 mM Tris-HCI, 1 mM EDTA (pH 8.0)).

(2) Preparation of gene library

[0118] A 50 µl portion of the chromosome DNA (1 µg/µl) obtained in the above (1), 20 µl of H buffer (500 mM Tris-HCi, 100 mM MgCl₂, 10 mM dithiothreitol, 1000 mM NaCl (pH 7.5)) and 8 units of a restriction enzyme Sau3Al (Takara Shuzo) were allowed to react at 37°C for 10 minutes in a total volume of 200 µl, and then 200 µl of the phenol/chloroform solution was added and mixed to stop the reaction. The reaction mixture was centrifuged, and the upper layer was collected and separated on a 0.8% agarose gel. DNA corresponding to 2 to 5 kilobase pair (henceforth abbreviated as "kbp") was collected by using Concert™ Rapid Gel Extraction System (DNA collecting kit, GIBCO BRL Co.). In this way, 50 µl of a solution of DNA with fractionated size was obtained.

[0119] On the other hand, 2.5 µg of plasmid pUC118 (Takara Shuzo), 2 µl of K buffer (200 mM Tris-HCl, 100 mM MgCl₂, 10 mM dithiothreitol, 1000 mM KCl (pH 8.5)) and 10 units of restriction enzyme *Bam*Hl (Takara Shuzo) were allowed to react at 37°C for 2 hours in a total volume of 20 µl, then 20 units of calf small intestine alkaline phosphatase (Takara Shuzo) was added and mixed, and the mixture was allowed to react for further 30 minutes. The reaction mixture was mixed with an equal amount of the phenol/chloroform solution, and the mixture was centrifuged. The supernatant was collected, and an equal amount of the chloroform solution was added thereto to repeat a similar extraction procedure. To the supernatant, a 1/10 volume of 3 M sodium acetate (pH 4.8) and 2.5-fold volume of ethanol were added to precipitate DNA. The DNA was collected by centrifugation, washed with 70% ethanol, dried under reduced pressure,

and dissolved in a suitable amount of TE solution.

[0120] A Sau3Al digestion product of the chromosome DNA prepared as described above and a BamHl digestion product of pUC118 were ligated by using a Ligation Kit ver. 2 (Takara Shuzo). To the reaction mixture, a 1/10 volume of 3 M sodium acetate (pH 4.8) and 2.5-fold volume of ethanol were added to precipitate DNA. The DNA was collected by centrifugation, washed with 70% ethanol, dried under reduced pressure, and dissolved in TE solution (Ligase solution A).

[0121] In the same manner as in the above procedure, fragments obtained by partial digestion of the chromosome DNA with a restriction enzyme *Alu*l (Takara Shuzo) and a *Sma*l digestion product of plasmid pSTV29 (Takara Shuzo) were ligated (Ligase solution B).

[0122] One platinum loop of *E. coli* JM109 was inoculated to 5 ml of L medium in a test tube, and cultured at 37°C overnight with shaking. The obtained culture broth was inoculated to 50 ml of L medium in a 500 ml-volume Sakaguchi flask in an amount of 1%, cultured at 37°C until OD₆₆₀ of the culture became 0.5 to 0.6, and cooled on ice for 15 minutes. Then, the cells were harvested by centrifugation at 4°C. The cells were suspended in 50 ml of ice-cooled water and centrifuged to wash the cells. This operation was repeated once again, and the cells were suspended in 50 ml of ice-cooled 10% glycerol solution, and centrifuged to wash the cells. The cells were suspended in 10% glycerol solution of the same volume as the cells, and divided into 50 µl aliquots. To the cells in the 50 µl volume, 1 µl of Ligase solution A or Ligase solution B prepared above was added. Then, the mixture was put into a special cuvette (0.1 cm width, preliminarily ice-cooled) for an electroporation apparatus of BioRad.

[0123] The setting of the apparatus was 1.8 kV and 25 μ F, and the setting of pulse controller was 200 ohms. The cuvette was mounted on the apparatus and pulses were applied thereto. Immediately after the application of pulse, 1 ml of ice-cooled SOC medium was added thereto, and the mixture was transferred into a sterilized test tube, and cultured at 37°C for 1 hour with shaking. Each cell culture broth was spread onto L agar medium containing an antibiotic (100 μ g/ml of ampicillin when Ligase solution A was used, or 20 μ g/ml of chloramphenicol when Ligase solution B was used), and incubated at 37°C overnight. The colonies emerged on each agar medium were scraped, inoculated to 50 ml of L medium containing respective antibiotic in a 500 ml-volume Sakaguchi flask, and cultured at 37°C for 2 hours with shaking. Plasmid DNA was extracted from each culture broth by the alkali SDS method to form Gene library solution A and Gene library solution B, respectively.

Example 7

•

30

Cloning of lysine biosynthesis gene of Methylophilus methylotrophus AS1 strain

(1) Cloning of gene coding for aspartokinase (AK)

[0124] E. coli GT3 deficient in the three genes coding for AK (thrA, metLM and tysC) was transformed with Gene library solution B by the same electroporation procedure as mentioned above. SOC medium containing 20 µg/ml of diaminopimelic acid was added to the transformation solution, and cultured at 37°C with shaking. Then, the culture broth was spread onto L medium containing 20 µg/ml of diaminopimelic acid and 20 µg/ml of chloramphenicol to obtain emerged colonies. This was replicated as a master plate to M9 agar medium containing 20 µg/ml of chloramphenicol, and the replicate was incubated at 37°C for 2 to 3 days. The host could not grow in M9 minimal medium that did not contain diaminopimelic acid since it did not have AK activity. In contrast, it was expected that the transformant strain that contained the gene coding for AK derived from Methylophilus methylotrophus could grow in M9 minimal medium because of the function of the gene

[0125] Two transformants out of about 3000 transformants formed colonies on M9 medium. Plasmids were extracted from the colonies emerged on M9 medium and analyzed. As a result, the presence of an inserted fragment on the plasmids was confirmed. The plasmids were designated as pMMASK-1 and pMMASK-2, respectively. By using these plasmids, *E. coli* GT3 was transformed again. The obtained transformants could grow on M9 minimal medium. Further, the transformant which contained each of these plasmids was cultured overnight in L medium containing 20 μg/ml of chloramphenicol, and the cells were collected by centrifugation of the culture broth. Cell-free extracts were prepared by sonicating the cells, and AK activity was measured according to the method of Miyajima et al. (Journal of Biochemistry (Tokyo), vol. 63, 139-148 (1968)) (Fig. 3: pMMASK-1, pMMASK-2). In addition, a GT3 strain harboring the vector pSTV29 was similarly cultured in L medium containing 20 μg/ml of diaminopimelic acid and 20 μg/ml of chloramphenicol, and AK activity was measured (Fig. 3: Vector). As a result, increase in AK activity was observed in two of the clones containing the inserted fragments compared with the transformant harboring only the vector. Therefore, it was confirmed that the gene that could be cloned on pSTV29 was a gene coding for AK derived from *Methylophilus methylotrophus*. This gene was designated as *ask*.

[0126] The DNA nucleotide sequence of the ask gene was determined by the dideoxy method. It was found that pMMASK-1 and pMMASK-2 contained a common fragment. The nucleotide sequence of the DNA fragment containing

the ask gene derived from Methylophilus methylotrophus is shown in SEQ ID NO: 5. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 5 and 6.

(2) Cloning of gene coding for aspartic acid semialdehyde dehydrogenase (ASD)

[0127] E. coli Hfr3000 U482 (CGSC 5081 strain) deficient in the asd gene was transformed by electroporation using Gene library solution B in the same manner as described above. To the transformation solution, SOC medium containing 20 µg/ml of diaminopimelic acid was added and the mixture was cultured at 37°C with shaking. The cells were harvested by centrifugation. The cells were washed by suspending them in L medium and centrifuging the suspension. The same washing operation was repeated once again, and the cells were suspended in L medium. Then, the suspension was spread onto L agar medium containing 20 µg/ml of chloramphenicol, and incubated overnight at 37°C. The host showed extremely slow growth in L medium not containing diaminopimelic acid since it was deficient in the asd gene. In contrast, it was expected that normal growth would be observed for a transformant strain which contained the gene coding for ASD derived from Methylophilus methylotrophus even in L medium because of the function of the gene. Further, the host E. coli could not grow in M9 minimal medium, but a transformant strain that contained the gene coding for ASD derived from Methylophilus methylotrophus was expected to be able to grow in M9 minimal medium because of the function of the gene. Therefore, colonies of transformants that normally grew on L medium were picked up, streaked and cultured on M9 agar medium. As a result, growth was observed. Thus, it was confirmed that the gene coding for ASD functioned in these transformant strains as expected.

[0128] Plasmids were extracted from the three transformant strains emerged on M9 medium, and the presence of an inserted fragment in the plasmids was confirmed. The plasmids were designated as pMMASD-1, pMMASD-2 and pMMASD-3, respectively. When the *E. coli* Hfr3000 U482 was transformed again by using these plasmids, each transformant grew in M9 minimal medium. Further, each transformant was cultured overnight in L medium containing 20 µg/ml of chloramphenicol, and the cells were collected by centrifugation of the culture broth. The cells were sonicated to prepare a crude enzyme solution, and ASD activity was measured according to the method of Boy et al. (Journal of Bacteriology, vol. 112 (1), 84-92 (1972)) (Fig. 4: pMMASD-1, pMMASD-2, pMMASD-3). In addition, the host harboring the vector was similarly cultured in L medium containing 20 µg/ml of diaminopimelic acid and 20 µg/ml of chloramphenicol, and ASD activity was measured as a control experiment (Fig. 4: Vector). As a result, the enzymatic activity could not be detected for the transformant harboring only the vector, whereas the ASD activity could be detected in three of the clones having an insert fragment. Therefore, it was confirmed that the obtained gene was a gene coding for ASD derived from *Methylophilus methylotrophus* (designated as *asd*).

[0129] The DNA nucleotide sequence of the *asd* gene was determined by the dideoxy method. It was found that all of the three obtained clones contained a common fragment. The nucleotide sequence of the DNA fragment containing the *asd* gene derived from *Methylophilus methylotrophus* is shown in SEQ ID NO: 7. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 7 and 8.

(3) Cloning of gene coding for dihydrodipicolinate synthase (DDPS)

35

40

[0130] E. coli AT997 (CGSC 4547 strain) deficient in the dapA gene was transformed by the same electroporation procedure using Gene library solution A. To the transformation solution, SOC medium containing 20 μg/ml of diaminopimelic acid was added, and the mixture was cultured at 37°C with shaking. Then, the culture broth was spread onto L medium containing 20 μg/ml of diaminopimelic acid and 100 μg/ml of ampicillin to obtain emerged colonies. This was replicated as a master plate to M9 minimal agar medium containing 100 μg/ml of ampicillin, and the replicate was incubated at 37°C for 2 to 3 days. The host could not grow in M9 minimal medium that did not contain diaminopimelic acid since it was deficient in dapA gene. In contrast, it was expected that a transformant strain that contained the gene coding for DDPS derived from Methylophilus methylotrophus could grow in M9 minimal medium because of the function of that gene.

[0131] Plasmids were extracted from the colonies of two strains emerged on M9 medium, and analyzed. As a result, the presence of an inserted fragment in the plasmids was confirmed. The plasmids were designated as pMMDAPA-1 and pMMDAP-2, respectively. When *E. coli* AT997 was transformed again by using these plasmids, each transformant was grown in M9 minimal medium. Further, each transformant containing each plasmid was cultured overnight in L medium containing 100 μ g/ml of ampicillin, and the cells were collected by centrifugation of the culture broth. The cells were sonicated to prepare a cell extract, and DDPS activity was measured according to the method of Yugari et al. (Journal of Biological Chemistry, vol.240, and p.4710 (1965)) (Fig. 5: pMMDAPA-1, pMMDAPA-2). In addition, the host harboring the vector was similarly cultured in L medium containing 20 μ g/ml of diaminopimelic acid and 100 μ g/ml of ampicillin, and DDPS activity was measured as a control experiment (Fig. 5: Vector). As a result, the enzymatic activity could not be detected for the transformant harboring only the vector, whereas the DDPS activity could be detected in each of the transformants harboring the plasmids having the insert fragment. Therefore, it was confirmed that the

obtained gene was a gene coding for DDPS derived from *Methylophilus methylotrophus* (designated as *dapA*). **[0132]** The DNA nucleotide sequence of the *dapA* gene was determined by the dideoxy method. It was found that two of the inserted fragments contained a common fragment. The nucleotide sequence of the DNA fragment containing the *dapA* gene derived from *Methylophilus methylotrophus* is shown in SEQ ID NO: 9. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 9 and 10.

(4) Cloning of gene coding for dihydrodipicolinate reductase (DDPR)

20

30

40

[0133] E. coli AT999 (CGSC 4549 strain) deficient in the dapB gene was transformed by the same electroporation procedure as described above using Gene library solution A. To the transformation solution, SOC medium containing 20 µg/ml of diaminopimelic acid was added, and the mixture was cultured at 37°C with shaking. Then, the cells were harvested by centrifugation. The cells were washed by suspending them in L medium and centrifuging the suspension. The same washing operation was repeated once again, and the cells were suspended in L medium. Then, the suspension was spread onto L agar medium containing 100 µg/ml of ampicillin, and incubated overnight at 37°C. The host showed extremely slow growth in L medium not containing diaminopimelic acid since it was deficient in the dapB gene. In contrast, it was expected that normal growth could be observed for a transformant strain that contained the gene coding for DDPR derived from Methylophilus methylotrophus even in L medium because of the function of the gene. Further, the host E. coli could not grow in M9 minimal medium, but it was expected that a transformant strain which contained the gene coding for DDPR derived from Methylophilus methylotrophus could grow in M9 minimal medium because of the function of the gene.

[0134] Therefore, a colony of transformant that normally grew on L medium was streaked and cultured on M9 agar medium. Then, growth was also observed on M9 medium. Thus, it was confirmed that the gene coding for DDPR functioned in the transformant strain. A plasmid was extracted from the colony emerged on M9 medium, and the presence of an inserted fragment in the plasmid was confirmed. When *E. coli* AT999 was transformed again by using the plasmid (pMMDAPB), the transformant grew in M9 minimal medium. Further, the transformant containing the plasmid was cultured overnight in L medium, and the cells were collected by centrifugation of the culture broth. The cells were sonicated to prepare a cell extract, and DDPR activity was measured according to the method of Tamir et al. (Journal of Biological Chemistry, vol. 249, p.3034 (1974)) (Fig. 6: pMMDAPB). In addition, the host harboring the vector was similarly cultured in L medium containing 20 µg/ml diaminopimelic acid and 100 µg/ml of ampicillin, and DDPR activity was measured as a control experiment (Fig. 6: Vector). As a result, the enzymatic activity could not be detected for the transformant harboring only the vector, whereas the DDPR activity could be detected for the transformant harboring pMMDAPB. Therefore, it was confirmed that the obtained gene was a gene coding for DDPR derived from *Methylophilus methylotrophus* (designated as *dapB*).

[0135] The DNA nucleotide sequence of the *dapB* gene was determined by the dideoxy method. The nucleotide sequence of the DNA fragment containing the *dapB* gene derived from *Methylophilus methylotrophus* is shown in SEQ ID NO: 11. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 11 and 12.

(5) Cloning of gene coding for diaminopimelate decarboxylase (DPDC)

[0136] E. coli AT2453 (CGSC 4505 strain) deficient in the *IysA* gene was transformed by the same electroporation procedure as described above using Gene library solution A. The transformation solution, SOC medium was added, and the mixture was cultured at 37°C with shaking. The cells were harvested by centrifugation. The cells were washed by suspending them in 5 ml of sterilized water and centrifuging the suspension. The same washing operation was repeated once again, and the cells were suspended in 500 µl of sterilized water. Then, the suspension was spread onto M9 minimal agar medium containing 20 µg/ml of chloramphenicol, and incubated at 37°C for 2 to 3 days. The host could not grow in M9 minimal medium not containing lysine since it was deficient in the *IysA* gene. In contrast, it was expected that a transformant strain that contained the gene coding for DPDC derived from *Methylophilus methylotrophus* could grow in M9 minimal medium because of the function of the gene.

[0137] Therefore, plasmids were extracted from the three transformant strains emerged on M9 medium, and analyzed. As a result, the presence of an inserted fragment in the plasmids was confirmed. The plasmids were designated as pMMLYSA-1, pMMLYSA-2 and pMMLYSA-3, respectively. When *E. coli* AT2453 was transformed again by using each of these plasmids, each transformant grew in M9 minimal medium. Further, each transformant containing each plasmid was cultured overnight in L medium containing 20 µg/ml of chloramphenicol, and the cells were collected by centrifugation of the culture broth. The cells were sonicated to prepare a cell extract, and DPDC activity was measured according to the method of Cremer et al. (Journal of General Microbiology, vol. 134, 3221-3229 (1988)) (Fig. 7: pMMLY-SA-1, pMMLYSA-2, pMMLYSA-3). In addition, the host harboring the vector was similarly cultured in L medium containing 20 µg/ml of chloramphenicol, and DPDC activity was measured as a control experiment (Fig. 7: Vector). As a

result, the enzymatic activity could not be detected for the transformant harboring only the vector, whereas the DPDC activity could be detected in three of the clones having an insert fragment. Therefore, it was confirmed that the obtained gene was a gene coding for DPDC derived from *Methylophilus methylotrophus* (designated as *lysA*).

[0138] The DNA nucleotide sequence of the *lysA* gene was determined by the dideoxy method. It was found that all of the three inserted fragments contained a common DNA fragment. The nucleotide sequence of the DNA fragment containing the *lysA* gene derived from *Methylophilus methylotrophus* is shown in SEQ ID NO: 13. An amino acid sequence that can be encoded by the nucleotide sequence is shown in SEQ ID NOS: 13 and 14.

Industrial Applicability

[0139] According to the present invention, there are provided a *Methylophilus* bacterium having L-amino acid-producing ability, a method for producing an L-amino acid using the *Methylophilus* bacterium, and *Methylophilus* bacterial cells with increased content of an L-amino acid. By the method of the present invention, it is enabled to produce an L-amino acid using methanol as a raw material. Moreover, novel L-lysine biosynthesis enzyme genes derived from *Methylophilus* bacteria are provided by the present invention.

SEQUENCE LISTING

5	<110> Ajinomoto Co., Inc.
10	<120> L-AMINO ACID-PRODUCING BACTERIUM AND METHOD FOR PRODUCING L-AMINO ACID
	<130> EPA-53711
15	<150> JP 11-103143 <151> 1999-04-09
20	<150> JP 11-169447 <151> 1999-06-16
25	<150> JP 11-368097 <151> 1999-12-24
	<160> 20
30	<170> PatentIn Ver. 2.0
	<210> 1
35	<211> 1197 <212> DNA <213> Escherichia coli
40	<220> <221> CDS <222> (272)(1147)
45	
	<400> 1 ccaggcgact gtcttcaata ttacagccgc aactactgac atgacgggtg atggtgttca 60 caattccacg gcgatcggca ccaacaggag tgatcagag atactgtgtt account at a contract of the contract of t
50	caattccacg gcgatcggca cccaacgcag tgatcaccag ataatgtgtt gcgatgacag 120 tgtcaaactg gttattcctt taaggggtga gttgttctta aggaaagcat aaaaaaaaaca 180 tgcatacaac aatcagaacg gttctgtctg cttgctttta atgccatacc aaacgtacca 240 ttgagacact tgtttgcaca gaggatggcc c atg ttc acg gga agt att gtc 292
55	Met Phe Thr Gly Ser Ile Val

										1				5			
	gc	att att	gtt	act	ccg	atg	gat	gaa	aaa	ggt	aat	tgto	tgt:	cgg	gct	agc	340
5	Ala	ı Ile			Pro	Met	Asp	Glu	Lys	Gly	' Asr	ı Val	Cys	Arg	Ala	Ser	
			10					15					20				
																atc	388
10	Let			Leu	lle	Asp			Val	Ala	Ser			Ser	Ala	Ile	
	4.4	25					30					35					
																gaa	436
15	va 1		Agi	uly	ınr	1nr 45	Gly	GIU	Ser	Ala			Asn	His	Asp	Glu	
15			øst	art a	ata		ato	200	ot a	mat	50		ant.			55	404
		gct														Ile	484
	1,10		nop	141	60	110 0	1100	1411	Deu	65		ı vıa	voh	alà	70		
20	ccg	gta	att	gcc		acc	ggc	gct	aac			PCF	gaa	ør.c			532
		Val		•										-		_	002
				75	•		•		80				•••	85		501	
25	ctg	acg	cag	cgc	ttc	aat	gac	agt	ggt	atc	gtc	ggc	tgc			gta	580
		Thr															
			90					95					100				
30	acc	cct	tac	tac	aat	cgt	ccg	tcg	caa	gaa	ggt	ttg	tat	cag	cat	ttc	628
	Thr	Pro	Tyr	Tyr	Asn	Arg		Ser	Gln	Glu	Gly	Leu	Tyr	Gln	His	Phe	
		105					110					115					
		gcc															676
35		Ala	He	Ala	Glu		Thr	Asp	Leu	Pro		He	Leu	Tyr	Asn		
	120		a m-1			125					130					135	
		tcc														_	724
10	rro	Ser	nig	1111	140	cys	nsp	Leu	Leu	145	GIU	Inr	vai	ыу	_	Leu	
	grø	aaa	øta	222		att	atc	002	atc		72 7	702	202	~~~	150	++-	779
		Lys															772
15		-, -		155			•••	4.,	160	2,0	UIU	ستنب	Y 111	165	noii	Leu	
	acg	cgt	gta		cag	atc	aaa	gag		gtt	tca	gat	gat		et.t.	ctg	820
		Arg														-	
			170				•	175				•	180				
i0	ctg	agc.	ggc	gat	gat	gcg	agc	gcg	ctg	gac	ttc	atg	caa	ttg	ggc	ggt	868
		Ser															
		185					190					195					
:5	cat	ggg	gtt	att	tcc	gtt	acg	act	aac	gtc	gca	gcg	cgt	gat	atg	gcc	916

	His 200		Val	He	Ser	Val 205		Thr	Asn	Val	Ala 210		Arg	Asp	Met	Ala	
5			+ 00	202	a t a			# 0.0		+						215	004
						Ala					Phe					gtt Val	964
	att	aat	cag	cgt			cca	tta	cac			cta	ttt	etc		ccc	1012
10					Leu					Asn					Glu	Pro	1012
	aat	cca	atc	ccg	gtg	aaa	tgg	gca	tgt	aag	gaa	ctg	ggt	ctt	gtg	gcg	1060
15				Pro					Cys					Leu		Ala	
	acc	gat	acg	ctg	cgc	ctg	cca	atg	aca	cca	atc	acc	gac	agt	ggt	cgt	1108
20	Thr	Asp 265	.Thr	Leu	Arg	Leu	Pro 270	Met	Thr	Pro	Ile	Thr 275	Asp	Ser	Gly	Arg	٠.
	gag	acg	gtc	aga	gcg	gcg	ctt	aag	cat	gcc	ggt	ttg	ctg	taa	agtt	tag	1157
	Glu	Thr	Val	Arg	Ala	Ala	Leu	Lys	His	Ala	Gly	Leu	Leu				
25	280					285	•				290						
	ggag	gatti	tga 1	tggc [.]	ttac	tc tį	gtte	aaaa	g tc	gcgc	ctgg						1197
30	<210)> 2															
		l> 2!														•	
		2> PI														•	
	<213	3> E:	schei	rich	ia co	oli											
35																	
	<400																
	Met	Phe	Thr	Gly		Ile	Val	Ala	Ile		Thr	Pro	Met	Asp	Glu	Lys	
40	1				5					10					15		
				20			•		25				Asp	30			
45	Ala	Ser	Gly 35	Thr	Ser	Ala	Ile	Val 40	Ser	Val	Gly	Thr	Thr 45	Gly	Glu	Ser	
	Ala	Thr 50	Leu	Asn	His	Asp	Glu 55	His	Ala	Asp	Val	Val 60	Met	Met	Thr	Leu	
50	Asp 65	Leu	Ala	Asp	Gly	Arg 70	Ile	Pro	Val	Ile	Ala 75	Gly	Thr	Gly	Ala	Asn 80	
	Ala	Thr	Ala	Glu	Ala, 85	Ile	Ser	Leu	Thr	G1n 90	Arg	Phe	Asn	Asp	Ser 95	Gly	
55	Ile	Val	Gly	Cys	Leu	Thr	Val	Thr	Pro	Tyr	Tyr	Asn	Arg	Pro	Ser	Gln	

			•	100					105					110			
	Glu	Gly	Leu	Tyr	Gln	His	Phe	Lys	Ala	Ile	Ala	Glu	His	Thr	Asp	Leu	
5			115					120					125		•		
	Pro	Gln	lle	Leu	Tyr	Asn	Val	Pro	Ser	Arg	Thr	Gly	Cys	Asp	Leu	Leu	
		130			•		135					140					
10	Pro	Glu	Thr	Val	Gly	Arg	Leu	Ala	Lys	Val	Lys	Asn	Ile	Ile	Gly	Ile	
	145					150					155					160	
	Lys	Glu	Ala	Thr	Gly	Asn	Leu	Thr	Arg	Val	aeA	Gln	Ile	Lys	Glu	Leu	
					165					170					175		
15	Val	Ser	Asp		Phe	Val	Leu	Leu	Ser	Gly	Asp	Asp	Ala	Ser	Ala	Leu	
				180					185					190			
	Asp	Phe		Gln	Leu	Gly	Gly		Gly	Val	Ile	Ser		Thr	Thr	Asn	
20			195					200					205				
	Val		Ala	Arg	Asp	Met		Gln	Met	Cys	Lys		Ala	Ala	Glu	Glu	
		210					215					220					
		Phe	Ala	Glu			Val	He	Asn	Gln		Leu	Met	Pro	Leu		
25	225	1	T	nL.		230	D	4	D	11.	235	V 1	.			240	
	ASI	Lys	Leu	rne	va1 245	GIU	Pro	ASI			Pro	val	Lys	Trp	Ala	Cys	
	Ive	Q1 ₁₁	Lan	Cl v		Va 1	Alo	Thn		250	T	A	T	Ď	255 Met	M L	
30	D) 3	oru,		260	DCU.	141	·NIG	1111	265	ш	ren	Arg	ren	270	met	Inr	
	Pro	He	Thr		Ser	Glv	Arg	Gln		Val	Arø	Ala	Ala		Lys	Hic	
			275		•••	,	•••	280					285	Deu	D , 3	1113	
35	Ala	Gly	Leu	Leu													
		290	•														
	<210	> 3															٠
40	<211	> 21	47														
	<212	> DN	A														
	<213	> Es	cher	ichi	a co	li											
45					`												
	<220																
		> CD															
50	<222	> (5	84).	.(19	30)												
			-														
	<400				_												
																tcatt	
<i>55</i>	agca	atac	tc t	tctg	attt	t ga	gaat	tgtg	act	ttgg	aag	attg	tagc.	gc c	agtc	acaga	120

	aaa	atgt	gat	ggtt	ttag	tg c	cgtt	agcg	t aa	tgtt	gagt	gta	aacc	ctt	agcg	cagtga	180
																ccccat	
5																gcaggc	
																cacctg	
•																gggggc	
																tggagc	
10																tcttcc	
															gaa		595
								•							Glu		
15								•					1				
	gtt	gtç	tcc	aaa	ttt	ggc	ggt	acc	agc	gta	gct	gat	ttt	gac	gcc	atg	643
	Val	Val	Ser	Lys	Phe	Gly	Gly	Thr	Ser	Val	Ala	Asp	Phe	Asp	Ala	Met	
20	5					10		•			15					20	
20	aac	cgc	agc	gct	gat	att	gtg	ctt	tct	gat	gcc	aac	gtg	cgt	tta	gtt	691
	Asn	Arg	Ser	Ala	Asp	Ile	Val	Leu	Ser	Asp	Ala	Asn	Val	Arg	Leu	Val	
			•		25			•		30					35		
25															tta		739
	Val	Leu	Ser		Ser	Ala	Gly	Ile	Thr	Asn	Leu	Leu	Val	Ala	Leu	Ala	
				40					45					50			
30															atc	· .	787
	Glu	Gly		Glu	Pro	Gly	Glu		Phe	Glu	Lys	Leu		Ala	Ile	Arg	
			55					60					65				
									•						gtt		835
35	Asn		Gin	Phe	Ala	He		Glu	Arg	Leu	Arg		Pro	Asn	Val	Ile	
		70					75					80					
															gca		883
40	85	GIU	alu	116	ulu		Leu	Leu	GIU	ASN		Inr	Val	ren	Ala	•	•
			~~~	a <del>+</del> #		90	+ . +				95			. <b>.</b>		100	004
															gtc Val		931
	nia	nia	Ala	ьсц	105	1111	261	110	nia	110	IIII.	Ÿaħ	GIU	Leu		ser	
45	cac	aar	gag	ctø		tra	200	cta	ot a		m++	<i>ana</i>	2+0	a+ ~	115 cgc		070
															Arg	_	979
	1113	OLJ	olu	120	neo	061	1111	Deu	125	1 116	Val	Ulu	116	130	MIR	GIU	
50	ር <b>ፓ</b> ር	gat	øtt		gra.	caø	too	+++		σta	cat	222	a+a		cgt		1007
															Arg		1027
	0	, top	135	4111	1114	9111		140	nop	197	ur 2		145	กร	urg	1111,	
55	aar	gar		ttt	øøt	cøt	pra		CC3	gat	ata			ctor	gcg	ga a	1075
		046	-94	•••	۰٥,	~6 V	6 ca	645	cua	5ut	ava	800	5 ⁵	UUB	508	Баа	1075

	Ası	150	Phe	Gly	Arg	Ala 155	Glu	Pro	Asp	Ile	Ala 160	Leu	Ala	Glu	
5		gcc Ala				Leu									1123
10		cag Gln								Gly		_	_		1171
15		cgt Arg											_		1219
20		gca Ala													1267
25		gat Asp 230													1315
30		gcc Ala													1363
		gca Ala												_	1411
35		tcc Ser					Ala								1459
40		gaa Glu				Phe								-	1507
<b>4</b> 5		ctg Leu 310			His					Leu					1555
50		gcg Ala		Phe					Arg				Val		1603
55		atc Ile						Val				Asp	acc	acc	1651

	ggt tca acc tcc act ggc gat acg ttg ctg acg caa tct ctg ctg atg 1699	)
_	Gly Ser Thr Ser Thr Gly Asp Thr Leu Leu Thr Gln Ser Leu Leu Met	
	360 365 370	
	gag ctt tcc gca ctg tgt cgg gtg gag gtg gaa gaa ggt ctg gcg ctg 1747	,
	Glu Leu Ser Ala Leu Cys Arg Val Glu Val Glu Glu Gly Leu Ala Leu	
10	375 380 385	
	gtc gcg ttg att ggc aat gac ctg tca aaa gcc tgc ggc gtt ggc aaa 1795	;
	Val Ala Leu Ile Gly Asn Asp Leu Ser Lys Ala Cys Gly Val Gly Lys	
15	390 395 400	
,5	gag gta ttc ggc gta ctg gaa ccg ttc aac att cgc atg att tgt tat 1843	
	Glu Val Phe Gly Val Leu Glu Pro Phe Asn Ile Arg Met Ile Cys Tyr	
	405 410 415 420	
20	ggc gca tcc agc cat aac ctg tgc ttc ctg gtg ccc ggc gaa gat gcc 1891	
•	Gly Ala Ser Ser His Asn Leu Cys Phe Leu Val Pro Gly Glu Asp Ala 425 430 435	
25	Glu Gln Val Val Gln Lys Leu His Ser Asn Leu Phe Glu	
	440 445	
	atggcctgga agctatattt cgggccgtat tgattttctt gtcactatgc tcatcaataa 2000	
	acgagectgt actetgttaa ceagegtett tateggagaa taattgeett taatttttt 2060	
30	atctgcatct ctaattaatt atcgaaagag ataaatagtt aagagaaggc aaaatgaata 2120	
	ttatcagttc tgctcgcaaa ggaattc 2147	
35	<210> 4	
	<211> 449	
	<212> PRT	•
40	<213> Escherichia coli	
	4400-	
	<400> 4	
	Met Ser Glu Ile Val Val Ser Lys Phe Gly Gly Thr Ser Val Ala Asp	
45	1 5 10 15	
	Phe Asp Ala Met Asn Arg Ser Ala Asp Ile Val Leu Ser Asp Ala Asn 20 25 30	
	Val Arg Leu Val Val Leu Ser Ala Ser Ala Gly Ile Thr Asn Leu Leu	
50	35 40 45	
	Val Ala Leu Ala Glu Gly Leu Glu Pro Gly Glu Arg Phe Glu Lys Leu	
55		

	65					70					75					80
5	Pro	Asn	Val	Ile	Arg 85		Glu	Ile	Glu	Arg 90		Leu	Glu	Asn	Ile 95	
	Val	Leu	Ala	Glu 100	Ala	Ala	Ala	Leu	Ala 105		Ser	Pro	Ala	Leu 110	Thr	Asp
10			115					120					125			
4.5		Leu 130					135					140				
15	145	Met				150					155					160
20		Leu			165					170					175	
		Leu		180					185					190		
25			195					200					205			
		Glu / 210					215		•			220	•			
30	225	Ile '				230					235					240
35	Asp				245					250					255	
05		Val I		260					265					270		
40			275					280					285			
		Cys A 290 Ang A					295					300				
45	Arg . 305					310					315					320
	Ser A				325					330				•	335	
50	Ile	, .	;	340					345				•	350		
55	Leu A	3	155					360					365			
30	Ser I	Leu L	eu 1	net	olu	Leu	ser	Ala	Leu	Cys .	Arg	Val	Glu	Val	Glu	Glu.

•	370 375 380														
	Gly Leu Ala Leu Val Ala Leu Ile Gly Asn Asp Leu Ser Lys Ala Cys														
5	385 390 395 400														
	Gly Val Gly Lys Glu Val Phe Gly Val Leu Glu Pro Phe Asn Ile Arg														
	405 410 415														
10	Met Ile Cys Tyr Gly Ala Ser Ser His Asn Leu Cys Phe Leu Val Pro														
	420 425 430														
	Gly Glu Asp Ala Glu Gln Val Val Gln Lys Leu His Ser Asn Leu Phe														
	435 440 445														
15	Glu														
20	<210> 5														
	<211> 1981														
	<212> DNA <213> Methylophilus methylotrophus														
25	<213> Methylophilus methylotrophus														
	(000)														
	<220>														
	<221> CDS														
30	<222> (510)(1736)														
	<400> 5														
35	gtttaacgcg gccagtgaat ttgactcggt cccctgcctg gcaaaatcgc acaggtgatg 60														
	gacaacgtga aatcgcttga aaaagaattg gcacgcctca agtccaagct ggcctcctca 120 cagggggatg acctcgcgac gcaagcgcag gacgtcaacg gcgccaaagt actggcagcc 180														
	accetegacy gggcggatge caatgeettg egtgaaacca tggataaget caaagataaa 240														
40	ctcaaatctg cagtcattgt gctggcgagc gtggctgacg gtaaagtcag cctggctgcg 300														
40	ggtgtcacta ctgacttgac tggcaaggtc aaagcaggcg aagttggtca atcatgtggc 360														
	tggtcaggtc ggtggcaaag gtggtggtaa accggatatg gcgatggcag gtggtactga 420														
	gcccgctaat ttgccgcagg ctttggcaag tgtgaaggct tgggtagaaa caaaactaaa 480														
45	ttaatttaat tgattaacag agcgaaata atg gca tta atc gta caa aaa tat 533														
	Met Ala Leu Ile Val Gln Lys Tyr														
	1 5														
50	ggt ggt acc tcg gtg gct aat ccc gag cgt atc cgt aat gtg gcg cgt 581														
	Gly Gly Thr Ser Val Ala Asn Pro Glu Arg Ile Arg Asn Val Ala Arg														
	10 15 20														
	cgc gtg gcg cgt tac aag gca ttg ggc cac cag gtg gtg gtt gtg gta 629														
55	Arg Val Ala Arg Tyr Lys Ala Leu Gly His Gln Val Val Val Val														

	25	5				30	)				35	;			•	40	
•	tcc	gca	ate	tet	ggt	gaa	acc	aac	cgg	ttg	ato	tca	cte	gco	aag	gaa	677
5																Glu	011
					45					50				,	55	•	
•	ato	atg	caa	gad	cct	gat	cca	cgt	gag	ctg	gat	gtg	ate	gta		acc	725
10																Thr	120
				60					65		·			70			
	ggt	gag	cag	gto	acc	atc	ggc	atg	acg	gcc	ctg	gca	ctg			ctt	773
		Glu															
15			75		,			80					85				
	ggc	att	aag	gca	aaa	agc	tat	acc	ggt	acc	cag	gtt	aag	atc	ttg	act	821
		Ile															
20		90					95					100					
	gac	gat	gct	ttt	acc	aag	gca	cgt	att	ctg	gat	atc	gac	gaa	cat	aac	869
	Asp	Asp	Ala	Phe	Thr	Lys	Ala	Arg	Ile	Leu	Asp	Ile	Asp	Glu	His	Asn	
	105					110					115					120	
25 ´	ctg	aaa	aaa	gac	ctg	gat	gat	ggc	tat	gtc	tgc	gtg	gtg	gct	ggg	ttc	917
	Leu	Lys	Lys	Asp		Asp	Asp	Gly	Tyr	Val	Cys	Val	Val	Ala	Gly	Phe	
					125					130			•		135		
30	cag																965
	Gln	Gly	Val		Ala	Asn	Gly	Asn	He	Thr	Thr	Leu	Gly	Arg	Gly	Gly	
				140		,			145					150			
		gat															1013
35	Ser	Asp		Thr	Gly	Val	Ala		Ala	Ala	Ala	Leu		Ala	Asp	Glu	
•	4.4		155					160					165				
		cag															1061
40	Uys	Gln	He	Tyr	Thr	Asp		Asp	Gly	Val	Tyr		Thr	Asp	Pro	Arg	
•		170					175					180					
		gtg															1109
45		Val	rro	GIU	Ala		Arg	Leu	Asp	Lys		Thr	Phe	Glu	Glu		
45	185		_1_	4		190					195					200	
		gaa															1157
	Leu	oıu	ren	Ala		ain	пl	26L			ren	GIN	He	Arg		Val	
50		111			205	<b>L</b>				210					215		
	gag																1205
	Glu	rne			гàг	lyr	Lys			Leu	Arg	Val			Ser	Phe	
55	<b>30</b> -			220		<b>-</b>			225					230			
	gaa	gag	gag	ggc	gac	ggt	aca	ctg	atc	aca	ttc	gaa	gaa	aat	gag	gaa	1253

	Glu	Glu	Glu 235	Gly	Asp	Gly	Thr	Leu 240	lle	Thr	Phe	Glu	Glu 245	Asn	Glu	Glu	
5	aac	atg		gaa	cca	att	atc		gge	atc	gee	ttt		ር <mark>ድ</mark> ሮ	gat	ga g	1301
										Ile							1001
		250					255		•			260		0	пор	VIQ	
10	gcg	aaa	att	acc	gtg	acg	ggc	gtg	ccc	gac	aaa	cca	gga	att	gcc	tat	1349
										Asp					-		
	265					270					275					280	
	cag	att	ttg	ggc	ccg	gtg	gca	gac	gcc	aat	att	gat	gtg	gat	atg	att	1397
15	Gln	He	Leu	Gly	Pro	·Val	Ala	Asp	Ala	Asn	lle	Asp	Val	Asp	Met	Ile	
					285					290					295		
										act						_	1445
20	Ile	Gln	,Asn		Gly	Ala	Asp	Gly		Thr	Asp	Phe	Thr	Phe	Thr	Val	
				300					305					310			
										agc							1493
25	His	Lys		Glu	Met	Asn	Lys		Leu	Ser	He	Leu		Asp	Lys	Val	
			315	_4_			4	320					325				
										agc						-	1541
	GIU	330	nis	116	UID	N18	335	GIU	116	Ser	GIY	<b>ASP</b> 340	ASP	Lys	116	Ala	
30	222		tet	ort or	σ++	a a a		a a t	ator	cgc	tca		ort a	aaa	0+0	<b>#</b> 00	1500
										Arg			_			•	1589
	345	, 4	501	,	,,,,,,,,	350	, ,	u.,	1100	6	355	1110	iar	UIJ	116	360	
35		cag	atg	ttc	cgt		ctg	gee	gaa	gaa		atc	aat	att	caa		1637
			•							Glu						_	1001
					365					370	•		•		375		
10	atc	tca	acc	agc	gaa	att	aaa	att	gca	gtc	gtg	atc	gaa	gag	aag	tac	1685
	Ile	Ser	Thr	Ser	Glu	Ile	Lys	He	Ala	Val	Val	Ile	Glu	Glu	Lys	Tyr	
				380					385					390			
	atg	gaa	ctg	gct	gta	cgc	gtg	ttg	cat	aaa	gca	ţtc	ggc	ctc	gaa	aac	1733
5	Met	Glu		Ala	Val	Arg	Val		His	Lys	Ala	Phe	Gly	Leu	Glu	Asn	
			395					400					405				
	gca	taat	cgcc	aa c	ggac	gaat	a aa	gaaa	taaa	aca	ittet	tct	tttt	tgcg	tt		1786
o	Ala																
																gcaaa	
																gaggg	
5						t go	aggo	atgo	aag	cttg	gcc	gtaa	tcca	tg g	tcat	agctg	
-	tttc	ctgg	tg t	gaaa	ì												1981

	<21	0> 6														
	<21	1> 4	09													
5	<21	2> P	RT													
	<21	3> M	ethy	loph	i lus	met	hylo	trop	hus							
10		0>-6														
	Met 1	Ala	Leu	Ile	Val 5	Gln	Lys	Туг	Gly	Gly 10	Thr	Ser	Val	Ala	Asn 15	Pro
15	Glu	Arg	Ile	Arg 20	Asn	Val	Ala	Arg	Arg 25	Val	Ala	Arg	Tyr	Lys 30		Leu
			Gln 35					40					45			
20	Arg	Leu 50	Ile	Ser	Leu	Ala	Lys 55	Glu	lle	Met	Gln	Asp 60	Pro	Asp	Pro	Arg
	Glu 65	Leu	Asp	Val	Met	Val 70	Ser	Thr	Gly	Glu	Gln 75	Val	Thr	Ile	Gly	Met 80
25	Thr	Ala	Leu	Ala	Leu 85	Met	Glu	Leu	Gly	Ile 90	Lys	Ala	Lys	Ser	Tyr 95	Thr
30	Gly	Thr	Gln	Val 100	Lys	lle	Leu	Thr	Asp 105	Asp	Ala	Phe	Thr	Lys 110	Ala	Arg
	Ile	Leu	Asp 115	He	Asp	Gļu	His	Asn 120	Leu	Lys	Lys	Asp	Leu 125	Asp	Åsp	Gly
35	Tyr	Val 130	Cys	Val	Val	Ala	Gly 135	Phe	Gln	Gly	Val	Asp 140	Ala	Asn	Gly	Asn
	11e 145	Thr	Thr	Leu	Gly	Arg 150	Gly	Gly	Ser		Thr 155	Thr	Gly	Val	Ala	Leu 160
40	Ala	Ala	Ala,	Leu	Lys 165	Ala	Asp	Glu	Cys	Gln 170	Ile	Tyr	Thr	Asp	Val 175	Asp
	Gly	Val	Tyr	Thr 180	Thr	Asp	Pro	Arg	Val 185	Val	Pro	Glu	Ala	Arg 190	Árg	Leu
45	Asp	Lys	Ile 195	Thr	Phe	Glu	Glu	Met 200	Leu	Glu	Leu	Ala	Ser 205	Gln	Gly	Ser
50	Lys	Val 210	Leu	Gln	Ile	Arg	Ser 215	Val	Glu	Phe	Ala	Gly 220	Lys	Tyr	Lys	Val
	Lys 225		Arg	Val	Leu	Ser 230	Ser	Phe	Glu	Glu	Glu 235		Asp	Gly	Thr	Leu 240
55		Thr	Phe	Glu	Glu	Asn	Glu	Glu	Asn	Met		Glu	Pro	Ile	Ile	

	245 250 255
5	Gly Ile Ala Phe Asn Arg Asp Glu Ala Lys Ile Thr Val Thr Gly Val 260 265 270
	Pro Asp Lys Pro Gly Ile Ala Tyr Gln Ile Leu Gly Pro Val Ala Asp 275 280 285
10	Ala Asn Ile Asp Val Asp Met Ile Ile Gln Asn Val Gly Ala Asp Gly 290 295 300
	Thr Thr Asp Phe Thr Phe Thr Val His Lys Asn Glu Met Asn Lys Ala 305 310 315 320
15	Leu Ser Ile Leu Arg Asp Lys Val Gln Gly His Ile Gln Ala Arg Glu 325 330 335
20	Ile Ser Gly Asp Asp Lys Ile Ala Lys Val Ser Val Val Gly Val Gly 340 345 350
20	Met Arg Ser His Val Gly Ile Ala Ser Gln Met Phe Arg Thr Leu Ala 355 360 365
25	Glu Glu Gly Ile Asn Ile Gln Met Ile Ser Thr Ser Glu Ile Lys Ile 370 375 380
	Ala Val Val Ile Glu Glu Lys Tyr Met Glu Leu Ala Val Arg Val Leu 385 390 395 400
30	His Lys Ala Phe Gly Leu Glu Asn Ala 405
	<210> 7
35	<211> 1452 <212> DNA <213> Methylophilus methylotrophus
10	<220> <221> CDS
15	<222> (98)(1207)
	<400> 7 gcatgcccgc aggtcgactc tagaggatcc ccctgttcaa aaatcttcca aataatcact 60
ro	gtaatgccgg gttgtccggc tgaaatatcg agtcact atg tta aaa gta ggg ttt 118  Met Leu Lys Val Gly Phe  1 5
: <b>5</b>	gta ggc tgg cgt ggc atg gtt gga tcc gtg cta atg cag cgc atg atg 163 Val Gly Trp Arg Gly Met Val Gly Ser Val Leu Met Gln Arg Met Met

				10	)				15	i				20	)		
	cag	gaa	aac	gat	ttţ	gcg	gat	att	gaa	cce	caa	tto	ttt	acg	acc	tca	211
5	Gln	Glu	Asn	Asp	Phe	Ala	Asp	Ile	Glu	Pro	Glm	Phe	Phe	Thr	Thr	Ser	
			25					30					35			•	
																ctg	259
10	Gln			Gly	Ala	Ala	Pro	Lys	Val	Gly	Lys	Asp	Thr	Pro	Ala	Leu	
		40					45					50					
																gtg	307
15			Ala	Lys	Asp			Ala	Leu	Arg	Gln		Asp	Val	Tle	Val	
.5	55					60					65					70	
											gtc				_	_	355
	Thr	Cys	Gin	Gly		Asp	Tyr	Thr	Ser			Phe	Pro	Gln		Arg	
20					75					80					85		
											gcg						403
	Ala	Im	GIY		9er	Gly	HIS	irp		Asp	Ala	Ala	Ser		Leu	Arg	
25	.+			90	<b>.</b>				95					100			
											ccg						451
	Met	AIA	105	waħ	ser.	Val	116	11e	rea	ASP	Pro	Yaı		met	HIS	val	
	att	222		gro a	++ a	ton	aat		<b>#</b> #0	222	aac	+	115				400
30											Asn						499
	110	120	nop	nia	Deu	DCI	125	ulj	01,	υya	VOII	130	116	gry	GIY	ASII	
	tet		gtc	tca	ctt	ate		atσ	grg	ntø	aat		cta	+++	220	go t	547
35											Asn						547
•	135		,		200	140	204		,,,,,	DCu	145	013	DCu	ine	μγο	150	
		ctg	gtc	gag	tgg		act	tcc	atg	acc	tac	cag	gcg	øct.	tca		595
											Tyr					-	000
10	-				155					160					165	41,	
	gca	ggc	gcg	cag	aat	atg	cgt	gaa	ctg		agc	cag	atg	egc		ete	643
											Ser						010
15		•		170					175					180			
•	aat	gcc	tcc	gtg	gct	gat	ttg	ctg		gat	cca	gct	tct		att	tte	691
											Pro						001
50			185					190		-			195				
	cag	atc.	gat	aaa	aca	gtg	gcg	gat	acc	atc	cgt	agc		gag	ttg	cct	739
	Gln																
		200					205					210					
5	aaa	tct	aac	ttt	ggt	gtg	cca	ttg	gcg	ggc	agt	ctg	atc	cca	tgg	atc	787
															_		

	215					220					225				Trp	230	
5	Asp	Lys	Asp	Leu	Gly 235	Asn	Gly	Gln	Ser	Lys 240	Glu	Glu	Trp	Lys	ggc Gly 245	Gly	835
10															gtg Val		883
15															caa Gln		931
20 .															aat Asn		979
25															gag Glu		1027
<i>.</i>															agt Ser 325	ctg	1075
30					ggg					ctg					gaa Glu		1123
35							Gly					Trp		gct	gcc Ala	-	1171
40	Pro		cgc	aga Arg		Leu	agg	att			Glu	tct		taat	tg		1217
45	ttta tgct	agta tttg gccg	gt g cc t	caat gggt	cctg gcgc	a gc t tt t tg	tatg aatg cgtg	gtta gctg	ttg ggt	tagc gaat	aaa ctc gat	tcat aaat gota	cctg tttt	ta t ga c	ttat aaac	gcttt tgctc gccat	1337
50	<210 <211 <212	> 37															
55	<213			ophi	lus	meth	ylot	roph	us					•	,		

	- 10	U> 8	,													
5	Met 1	Leu	Lys	Val	Gly 5		Val	Gly	Trp	Arg 10		Met	Val	Gly	Ser 15	Val
	Leu	Met	Gln	Arg 20		Met	Gln	Glu	Asn 25		Phe	Ala	Asp	Ile 30	Glu	Pro
10	Gln	Phe	Phe 35		Thr	Ser	Gln	Thr 40		Gly	Ala	Ala	Pro 45	Lys		Gly
	Lys	Asp 50		Pro	Ala	Leu	Lys 55	Asp	Ala	Lys	Asp	Ile 60			Leu	Arg
15	Gln 65			Val	Ile	Val 70		Cys	Gln	Gly	Gly 75		Tyr	Thr	Ser	Asp 80
20	Val	Phe	Pro	Gln	Leu 85	Arg	Ala	Thr	Gly	Trp 90	Ser	Gly	His	Trp	Ile 95	Asp
	Ala	Ala	Ser	Thr 100	Leu	Arg	Met	Glu	Lys 105	Asp	Ser	Val	Ile	Ile 110		Asp
25	Pro	Val	Asn 115	Met	His	Val	Ile	Lys 120	Asp	Ala	Leu	Ser	Asn 125		Gly	Lys
	Asn	Trp 130	Ile	Gly	Gly	Asn	Cys 135	Thr	Val	Ser	Leu	Met 140	Leu	Met	Ala	Leu
30	Asn 145	Gly	Leu	Phe	Lys	Ala 150	Asp	Leu	Val	Glu	Trp 155		Thr	Ser	Met	Thr 160
35	Tyr	Gln	Ala	Ala	Ser 165	Gly	Ala	Gly	Aļa	Gln 170	Asn	Met	Arg	Glu	Leu 175	Ile
	Ser	Gln	Met	Gly 180	Val	Val	Asn	Ala	Ser 185	Val	Ala	Asp	Leu	Leu 190	Ala	Asp
40	Pro	Ala	Ser 195	Ala	Ile	Leu	Gln	Ile 200	Asp	Lys	Thr	Val	Ala 205	Asp	Thr	Ile
	Arg	Ser 210	Glu	Glu	Leu	Pro	Lys 215	Ser	Asn	Phe	Gly	Val 220	Pro	Leu	Ala	Gly
45	Ser 225	Leu	Ile	Pro		Ile 230	Asp	Lys	Asp	Leu	Gly 235	Asn	Gly	Gln	Ser	Lys 240
	Glu	Glu	Trp	Lys	Gly 245	Gly	Val	Xaa		Asn 250	Lys	Ile	Leu	Gly	Arg 255	
50	Ala	Asn	Pro	Ile 260	Val	Ile	Asp	Gly	Leu 265	Cys	Val	Arg	Ile	Gly 270		Met
55	Arg	Cys	His 275	Ser	Gln	Ala		Thr 280		Lys	Leu	Arg	Lys 285		Val	Pro

```
Leu Asp Glu Ile Asn Gln Met Leu Ala Glu Ala Asn Asp Trp Ala Lys
               290
                                   295
                                                       300
          Val Ile Pro Asn Glu Arg Glu Val Ser Met Arg Glu Leu Thr Pro Ala.
 5
                               310
                                                   315
          Ala Ile Thr Gly Ser Leu Ala Thr Pro Val Gly Arg Leu Arg Lys Leu
                           325
                                               330
                                                                   335
10
          Ala Met Gly Gly Glu Tyr Leu Ser Ala Phe Thr Val Gly Asp Gln Leu
                       340
                                           345
          Leu Trp Gly Ala Ala Glu Pro Leu Arg Arg Met Leu Arg Ile Leu Val
15
                  355
                                       360
                                                           365
          Glu Ser
              370
20
          <210> 9
          <211> 3098
          <212> DNA
25
          <213> Methylophilus methylotrophus
          <220>
          <221> CDS
30
          <222> (1268)..(2155)
          <400> 9
35
          cgtgccaact tgcatgcctg ccggtcgctc tagaggatca attgctggca acatttgagt 60
          acattattcg cctttgcatg gtaaaggcct atggtcttga tgtaactttc aagacctgcc 120
          agccccaaat ccaggatagc ctgcggtgtg ttggccacct tgaacaattt gcgggtggca 180
          atattgacac ctttgtctgt cgcctgtgca gacaagatga cggcaatcag taattcgaac 240
40
          gtggagctat gctccagctc agtggttgga ttggggatgg cttgggccag ccgctcaaat 300
          atcgccagtc ttttttgtgc attcataaaa cggtttcaat cataggtcac agggtcaacc 360
          tgtcttttgc gctttgacgc gcgccatggc tgcggcaatg gcatttttct tgagcacctc 420
45
          agttgagggt gtctcggtcg tagcaagcgt ctggttgcgt ttgctgtagg tttgggcggt 480
         ctcccgtttt tcaagggcga ggcgagaaag gcgttgctgg tggcgttgtc tcgctaccgc 540
         ggcttcagct tcattcatgg cggtagcccg accgggaatc gtttgcatct gtatgcagtc 600
         caccgggcag ggcggtaaac atagctcaca gccagtgcat tcctgggaaa tcaccgtatg 660
50
         catcagtttg gatgcgccca aaatggcatc aacgggacag gcctgtatac acagggtgca 720
         gccgatgcat gtttcctcat caatcaaggc caccgctttg ggtttggtga tgccgtgggc 780
         cggatttaat gcctggaaag gacgttgcag taatttggca agcgcatgaa tgcccgcttc 840
55
         tectecagge ggacattggt tgatattgge eteteegegg gegategett cageataagg 900
```

	ttt	gcat	ccc	tcgt	aacc	gc a	ittgg	cggc	a ti	gagt	ttgo	ggt	aata	eccg	cgtc	gatctt	960
																aatcat	
5	gtg	atgg	cag	gtga	gtct	gc a	ttcg	gtcc	t gg	ctaa	atag	CCE	ttta	aga	tggg	ttgcta	1080
																aaaagc	
																agatac	
10																tttatt	
	ctt	aaag	atg	gcg	cta	ggt	atg	tta	acg	ggc	agt	ttg	gtc	gca	atc	gtg	1309
			Met	Ala	Leu	Gly	Met	Leu	Thr	Gly	Ser	Leu	Val	Ala	lle	Val	
			1				5					10					
15														ctc			1357
		Pro	Met	Phe	Glu	Asp	Gly	Arg	Leu	Asp	Leu	Asp	Ala	Leu	Lys	Lys	
	15					20					25					30	
20														gtc			1405
•	Leu	Val	Asp	Phe		Val	Glu	Ala	Gly		Asp	Gly	lle	Val		Val	•
			+		35	<b>.</b>			_4	40					45		
25														cat			1453
	uly	I III .	1111	50	OIU	261.	rro	ш	55 55	ASP	Val	ASP	u	His	Cys	Leu	
	ctø	atc	222		800	atc	020	rat	_	<b>700</b>	220	000	a+ a	60 cca	+-	-++	1501
٠														Pro			1501
30			65	••••	****	110	Ulu	70	141	nia	цуз	мę	75	110	Val	116	
	gcc			ggc	gca	aat	tcc		gct	gaa	gcc	att		ctg	act	gcc	1549
														Leu			1043
35		80		-			85		•			90					
	aag	gcc	aag	gcg	ctt	ggc	gca	gac	gcc	tgc	ctg	ctg	gtg	gca	ccg	tat ·	159 <del>7</del>
														Ala			
40	95					100					105					110	
40	tac	aac	aag	ccc	tcg	caa	gag	ggt	ttg	tac	cag	cac	ttt	aaa	gcc	gtg	1645
	Tyr	Asn	Lys	Pro		Gln	Glu	Gly	Leu	Tyr	Gln	His	Phe	Lys	Ala	Val	
					115					120					125		
45	gct																1693
	Ala	Glu	Ala		Asp	Ile	Pro	Gln		Leu	Tyr	Asn	Val	Pro	Gly	Arg	
				130					135					140			
50	acc																1741
	Thr			Asp	Leu	Ser			Thr	Val	Leu			Ala	Gln	lle	
			145					150					155				
	cgc																1789
55	Arg	ASN	116	val	Gly	116	Lys	Asp	Ala	Thr	Gly	Gly	He	Glu	Arg	Gly	

		·			
		•			
·		•			
	·				·
					•
•				•	

		160					165					170					
	acc	gat	ttg	ttg	ttg	cgt	gca	cca	gct	gat	ttc	gcc	att	tac	agc	ggg	1837
5															Ser		
	175					180					185					190	•
	gat	gat	gcc	act	gcg	ctg	gcc	ctg	atg	tta	tta	ggg	ggg	aaa	ggc	gtg	1885
10															Gly		- 445
70					195					200				•	205		
	att	tcg	gtc	acg	gcc	aat	gtc	gcg	ccc	aaa	tta	atg	cat	gaa	atg	tgc	1933
															Met		
15	٠			210					215					220		. •	
•	gag	cat	gct	ttg	aat	ggc	aac	ctg	gcc	gca	gcc	aaa	gcg	gcc	aat	gcc	1981
															Asn		
20			225					230					235				
	aaa	ctg	ttt	gca	ttg	cac	cag	aag	ttg	ttt	gta	gaa	gcg	aac	ccg	att	2029
	Lys																
		240					245	•				250					
25	cca	gtg	aaa	tgg	gta	tta	caa	caa	atg	gga	atg	att	gcc	act	ggc	atc	2077
	Pro	Val	Lys	Trp	Val	Leu	Gln	Gln	Met	Gly	Met	Ile	Ala	Thr	Gly	Ile	
	255					260					265					270	
30 ·	cgt	ttg	ccg	ctg	gtc	aat	tta	tcc	agc	caa	tat	cat	gaa	gta	ttg	cgc	2125
	Arg	Leu	Pro	Leu	Val	Asn	Leu	Ser	Ser	Gln	Tyr	His	Glu	Val	Leu	Arg	
					275					280					285		
	aac	gcc	atg	aag	cag	gca	gaa	att	gcc	gct	tgat	cggc	ta a	aact	aatt	t	2175
35	Asn	Ala	•		Gln	Ala	Glu	Ile	Ala	Ala							
				290					295								
																ccagt	
40																actac	
																gtacc	
																aggaa	
																tggtg	
45																cgatt	
																ttggc	
																gtggc	
50																gtaaa	
	ttcc	gtac	gc g	tctg	gaac	g tg	ggga	gaaa	gac	ggca	cca	ccga	aatc	ta t	atga	cgcac	2775
																gtgtc	
																agttt	
55	gatgo	etga	ct t	ggat	gcag	a at	tact	ccgt	cga	atga	tgg	tgaa	atta	gg t	ctgg	atgag	2955

5	cagaaaq gagtotq gtggco	gacc ag	gagogto	ac c	ttga										
10	<210> 1 <211> 2 <212> E <213> E	296 PRT	philus	met	hylo	trop	hus								
15	<400> 1 Met Ala		lly Met	Leu	Thr	Gly	Ser	Leu	Val	Ala	Ile	Val	Thr	Pro	
20	1 Met Phe		5					10					15		
25	Asp Phe	35				40					45		-		
	50 Lys Thr 65				55					60					
<b>30</b>	Thr Gly		. 85	Thr				90	Glu				95	Ala	
35	Lys Ala	1 Ser G	00			Tyr	105				Ala	110		•	
40	Ala Val	•			135					140				-	
<b>4</b> 5	Cys Asp 145 Ile Val			150					155					160	
	Leu Leu	,	165 rg Ala 80	Pro	Ala	Asp	Phe 185	170 Ala	Ile	Tyr	Ser	Gly 190	175 Asp		
50	Ala Thr	Ala L 195	eu Ala			200	Leu				205	Val			
55	Val Thr 210	A18 A	sn val		Pro 215	Lys	Leu	Met	His	Glu 220	Met	Cys	Glu	His	

```
Ala Leu Asn Gly Asn Leu Ala Ala Ala Lys Ala Ala Asn Ala Lys Leu
           225
                                230
                                                    235
                                                                        240
           Phe Ala Leu His Gln Lys Leu Phe Val Glu Ala Asn Pro Ile Pro Val
                            245
                                                250
           Lys Trp Val Leu Gln Gln Met Gly Met Ile Ala Thr Gly Ile Arg Leu
                        260
                                            265
                                                                270 -
 10
           Pro Leu Val Asn Leu Ser Ser Gln Tyr His Glu Val Leu Arg Asn Ala
                   275
                                        280
                                                            285
           Met Lys Gln Ala Glu Ile Ala Ala
15
               290
                                   295
           <210> 11
           <211> 3390
20
           <212> DNA
           <213> Methylophilus methylotrophus
25
           <220>
           <221> CDS
           <222> (2080)..(2883)
30
           <400> 11
           ccgcaggtcg ctctagagga tcagagttgg acggacaagc tgaagttttg ggagtctgaa 60
           gaagctgcgg gcgaagtgat aaagcagctg aatcaactgt agccactgca agcgacgaat 120
           gaaagcaaag gcgctgcact cgctaaggat gaggcagccg aatctcagaa aaccacgtca 180
35
           gagoctgtca aggocgagoa agaggtattg coctoggoca ctgcaacaaa taattcagot 240
           gctgcagcga cattggctga agaagaagtg gttccctaca ttccggaggg ggagtatcag 300
           gctgcaccca ctccagaaga gatggccaag ggtaatctgg atgtcagtga aaaccaggtt 360
40
           actgaggeta aggeacatee agtgaatgaa aaggaaatgg etgeecaaat tgeagataeg 420
           gttgagccac caccogtttt tcagcaggaa ccgatggcag aacctattgt agcggctgaa 480
           cccgaacccg tattgccacc gcccgtaaaa gccgaaccag ctgtgaagaa tatcacagcg 540
           ccagttgttg ccgcagccac tgttgcagcg gcggcaacca agactgctga atctgagtca 600
45
          gttaaatcca aacctgttga tcctaagcct gtggaagcaa aaaccgctgt atcaaaaact 660
          gaagtacaaa cacccgcggc acaggcacct gctgcggcag cggccgttga agatgacgag 720
          gtcattccat atattcccga aggtgaatat gtggctcctg tcattcctag tgaggccgaa 780
50
          atggttaaag gcaatatggc ggaggcaaat gcacctgcga ctgatgctca agcgcgccag 840
          gtaactgaaa aaggggtggc acceacatcg gatgcggcag cagagccatc accgacattt 900
          gtcgctgagc aattgccaga accagagcca gaacctgaat tgccaccgcc gcctccgcca 960
          tccgtcagca agcctgttgt gagagaggta gcgccagtgg ctgcgctggc agcagaagaa 1020
55
```

	gag	aaac	cag	tcgc	tgcg	ca g	cctg	agac	t ga	gcag	ccgg	ctg	ccaa	ggt	tgtt	gagcct	1080
	gca	tcgg	tcg	cctc	ccct	gt g	gcga	cgcc	a ga	agcg	ccag	ctg	gtga	tgc	tgaa	atcaac	1140
5	cag	gctg	tgg	cggc	atgg	gc a	caag	cttg	g cg	cage	aagg	aca	ttaa	aaa	ctac	ctcgct	1200
	gca	tatg	ÇÇC	ctga	cttc	at g	ccag	aagg	g tt	gcct	tcca	gaa	aggc	atg	ggag	tcgcaa	1260
	cgc	aaac	agc	gttt	atct	gc a	ggcc	aggg	t gc	gatt	acac	tcg	tact	aaa	taat	gtgcag	1320
10	att	cago	gtg	acgg	tacc	ac t	gtcg	ccgt	g ca	gttt	gagc	aaa	aata	tgc	tgct	aaagtt	1380
70	tata	aaag	atg	aatt	ggtc	aa a	acac	tgga	a at	gcgt	tacg	ago	caac	gca	gaaa	cgttgg	1440
	ttg	atca	cac	gtga	acgt	gt t	gccc	cttt	a ac	cggt	ttgc	cag	tagc	gag	tgtg	ccaacg	1500
	acc	cgtc	tgc	cagc	agtc	gc t	gcag	cgtc	a tc	caat	acgg	atg	tggt	cga	gtca	gctgtg	1560
15	cca	ccga	cac	aatc	gaca [.]	tc a	tctg	cgcc	t gt	agcg,	gaag	tga	gtgt	tga	atca	gcgatt	1620
	gac	gcct	ggg	caca	ggct	tg g	cgca	gtaa	a aa	catc	aatg	ctt	actt	tgc	ggcg	tattct	1680
	ccat	gaat	ttg	tgcc	ggagi	gg a	ttgc	caaa	c ag	aggt	gtct	ggg	aagc	gca	acgt	aaaaag	1740
20																agccgc	
20																cgtgat	
																attgtg	
																gcgcca	
25																tctgct	2040
	gate	tcgt	tgg	tttaa	agtat	tt a	aaaa	taat	t ga	gtga					gta (		2094
		,									1	let	Leu ]	Lys	Val '		
30												1				5	
															gga	-	2142
	116	Ala	GIY	yaı		,61y	Arg.	met	Gly		Ala	Leu	Leu.	Asp	Gly	Val	
	111	<b>L</b> _L			10	***		44		15					20		
35														-	gct	-	2190
	rne	26L	ASP	ASN 25	GIY	ren	GIN	Leu		AIA	ATB	Leu	ASP		Ala	Glu	
		<b>~~</b>	^+=		~~~		<b>~</b> ^+	<b>700</b>	30			***		35			0000
40															gtc	-	2238
	set.	Ala	40	116	GIŞ	Arg	ASP	45	GIY	GIU	uin	rne		Lys	Val	Ser	
	aa.	art ar		ato	9.00	ac+	ga.		oot	<b></b>	<b>400</b>	++	50		gcc	4	0000
																	2286
45	013	55	DJS	116	IIII	VIT	45v	116	1112	nia	ula	65	Val	игу	Ala	Asp	
	at a		at a	ga t	t to	200		000	<b>#22</b>	<b>700</b>	0 m t		200	4.4	44.		0004
															tta	,	2334
50		Leu	141	voħ	rne	75	MIR	rro	uıu	HIA		nec	atu	lyr	Leu		
	70 <b>7</b> 0	tan	024	000	<b>700</b>		a++	200	++^	at a	80	~~+	0.04	000		85	0.000
															ggg		2382
	urg	υys	AIII	OIII	90	กรม	141	гìЯ	שמע		116	oly	INC	ınr	Gly	rne	
<b>55</b>					JU					95					100		

	agt	gag	gca	gaa	aag	gcc	agt	att	gag	gct	gcg	tcc	aaa	aat	atc	ggt	2430
	Ser	Glu	Ala	Glu	Lys	Ala	Ser	Ile	Glu	Ala	Ala	Ser	Lys	Asn	He	Gly	
5				105					110					115			
	atc	gta	ttt	gct	cca	aac	atg	agc	ġta	ggg	gtc	acc	ctc	ttg	att	aac	2478
•																Asn	
10			120					125					130				
	ctg	gtt	gag	caa	gcc	gca	cgg	gtg	ctc	aat	gaa	ggc	tat	gat	att	gag	2526
		Val															
		135					140					145	·	•			
15	gtg	gt <b>t</b>	gaa	atg	cat	cac	cgc	cat	aag	gtg	gat	gcg	cct	tca	ggc	acg	2574
		Val															
	150					155					160					165	
20	gct	tta	cgg	ttg	ggt	gag	gct	gcg	gca	aaa	ggg	att	gat	aaa	gcg		2622
20		Leu															
	•				170					175			-	-	180		
	aaa	gat	tgt	gct	gtg	tat	gcg	ċgc	gaa	ggc	gtg	act	ggt	gaa		gaa	2670
25		Asp															
				185					190					195	_		
	gcg	ggc	acg	att	ggt	ttt	gca	acc	tta	cgt	ggt	ggg	gat	gtg	gtc	ggt	2718
		Gly															
30			200					205					210			-	
	gac	cat	acg	gtg	gtt	ctg	gct	ggt	gtg	ggt	gag	cga	gta	gag	tta	acg	2766
		His															
35		215					220					225					
	cat	aaa	gca	tca	agc	cgt	gcc	aca	ttt	gca	caa	ggt	gcg	tta	cgt	gcg	2814
	His	Lys	Ala	Ser	Ser	Arg	Ala	Thr	Phe	Ala	Gln	Gly	Ala	Leu	Arg	Ala	
	230					235					240					245	
40	gct	aaa	t <b>t</b> t	ctg	gct	gat	aaa	ccc	aag	gga	ttg	ttt	gat	atg	cgt	gat	2862
	Ala	Lys	Phe	Leu	Ala	Asp	Lys	Pro	Lys	Gly	Leu	Phe	Asp	Met	Arg	Asp	
					250					255				•	260		
45	gtg	ttg	gga	ttt	gaa	aag	aac	tgat	cttt	ag t	aggc	gatc	c cg	tctg	gcta		2913
	Val																
				265													
	aggt	ctgg	ca g	gaat	cgtc	t ga	tgct	tctg	agt	tgcc	ctt ,	gagt	gggc	tg t	caat	gtacg	2973
50																acatc	
																gtttc	
																agcag	
55																ggtgg	
							_	-							J - U =	-00	

5	aaa	atcgt		actg	acct	at c	cgca	catt	g gt	aact	acgg	gac	caat	cgt	gaag	iccgaac Katggga Laag	
70	<21 <21	0> 1 1> 2 2> P 3> M	68	loph	ilus	met	hylo	trop	hus								
15	<40	0> 1	2														
	1	•			5					10					15		
20	Leu	Leu	Asp	Gly 20	Val	Phe	Ser	Asp	Asn 25	Gly	Leu	Gln	Leu	His		Ala	
·	Leu	Asp	Arg 35	Ala	Glu	Ser	Ala	Met 40	Ile	Gly	Arg	Asp	Ala 45			Gln	
25	Phe	Gly 50		Val	Ser	Gly	Val 55	Lys	Ile	Thr	Ala	Asp 60	Ile	His	Ala	Ala	
	Leu 65		Gly	Ala	Asp	Val 70	Leu	Val	Asp	Phe	Thr 75	Arg	Pro	Glu	Ala	Ser 80	
30			Tyr	Leu	Gln .85.		Cys	Gln	Gln	Ala 90		Val	Lys	Leu	Val 95	Ile	
35	Gly	Thr	Thr	Gly 100	Phe	Ser	Glú	Ala	Glu 105	Lys	Ala	Ser	Ile	Glu 110			
	Ser	Lys	Asn 115	Ile	Gly	Ile	Val	Phe 120	Ala	Pro	Asn	Met	Ser 125	Val	Gly	Val	
40	Thr	Leu 130	Leu	Ile ·	Asn	Leu	Val 135	Glu	Gln	Ala	Ala	Arg 140		Leu	Asn	Glu	
	Gly 145		Asp	Ile	Glu	Val 150		Glu	Met	His	His 155		His	Lys	Val	Asp 160	
<b>45</b>	Ala	Pro	Ser	Gly	Thr 165	Ala	Leu	Arg	Leu	Gly 170	Glu	Ala	Ala	Ala	Lys 175	Gly .	
50	Ile	Asp	Lys	Ala 180	Leu	Lys	Asp	Cys	Ala 185	Val	Tyr	Ala	Arg	Glu 190		Val	
	Thr	Gly	Glu 195		Glu	Ala	Gly	Thr 200		Gly	Phe	Ala	Thr 205		Arg	Gly	
55	Gly	Asp 210	Val	Val	Gly		His 215	Thr	Val	Val	Leu	Ala 220		Val	Gly	Glu	

Arg Val Glu Leu Thr His Lys Ala Ser Ser Arg Ala Thr Phe Ala Gln 225 230 235 240 Gly Ala Leu Arg Ala Ala Lys Phe Leu Ala Asp Lys Pro Lys Gly Leu 5 245 250 Phe Asp Met Arg Asp Val Leu Gly Phe Glu Lys Asn 260 265 10 <210> 13 <211> 2566 15 <212> DNA <213> Methylophilus methylotrophus <220> 20 <221> CDS <222> (751)..(1995) 25 <400> 13 tgctttaggg ggaacctaga ggatcccct acccgaggaa gaagtgagcc aacatgtact 60 tccagtcgta ccatcaaaag tagaagtttt cggcgttatc ctgattcaca gtaaacgaaa 120 aattgcccat attctgaccg gatttaccgg tggcttttaa ggtataagtg gtcgctgact 180 30 ggttctcaat gctgtaatca aaaaatttgg catcactggg gacacaggca aatcccacat 240 atgtgaagtt gtcctgataa aactgttcgg cctgcacacg gcaattggca agattggcag 300 gegetteege ggeattaceg ettttgatgt aateetgata geetggtatg gegatgetgg 360 ccaagatacc cataatggcc accacgacca tgacttctat caggctgaat ccgtactgat 420 35 ttgaggactt cattatcaaa ccccttttta gatagcctta tcatgcaaac aggcagctgt 480 catgtccagc atcagccgac caatggtcag gattacccga cgaacggtca aaccactaaa 540 acgcccagtc actggtgcca tgagcaactg caggtttaat gataaaatgg cactcaattt 600 40 acattggact gtgaacatgt tttccttcta tacgagatta ttggcggttg ccctgctatt 660 ggcacaattg agtgcctgtg gtctcaaagg ggacctgtat attcctgagc gccaataccc 720 tcaaacgcct caacaagata agtcttcatc gtg acc gct ttt tca atc caa caa 774 45 Val Thr Ala Phe Ser Ile Gln Gln 1 5 ggc cta cta cat gcc gag aat gta gcc ctg cgt gac att gca caa acg 822 Gly Leu Leu His Ala Glu Asn Val Ala Leu Arg Asp Ile Ala Gln Thr 50 15 20 cat caa acg ccc act tac gtc tat tca cgt gcc gcc ttg acg act gct 870 His Gln Thr Pro Thr Tyr Val Tyr Ser Arg Ala Ala Leu Thr Thr Ala 25 55 30 35 40

																tgc Cys	918
5		, 010			45		. 01)	БСС	. 1111	50		, vsh	1118	. Let	55 55	-	
	ttt	gct	gto	aaa	gcc	aac	cca	agc	ctg	gcc	att	ctc	aac	ctg	ttt	gcg	966
	Phe	Ala	Val	Lys	Ala	. Asn	Pŗo	Ser	Leu	Ala	Ile	Leu	Asn	Lev	Phe	Ala	•
10				60		-			65					70			
																cgc	1014
	Arg	Met			Gly	Phe	Asp			Ser	Gly	Gly	Glu	Leu	Ala	Arg	
45	-4-		75					80					85				
15																gtg	1062
	Val	Pen Pen	Ala	Ala	GIY	GIY	_	rro	Lys	Lys	Val		Phe	Ser	Gly	Val	
				cat	ana	œn.	95	000	<b>500</b>	~~~	.++	100			. 4.1		
20																ctt Leu	1110
	105		001	ms	MIG	110	116	כנע	uta	VIT	115	ara	Ala	GIÀ	iie		
			aac	gtg	gaa		ete	aat	gag	cta		ርምር	atc	ലമ	naar	120	1150
25			Asn														1158
	-		, .		125					130		**** 6		0111	135	VUI	
	gcg	gcc	agc	ctg	ggç	aaa	aaa	gcg	cct	att	tcc	ctg	cgc	gtg	aac	ccc	1206
30	Ala	Ala	Ser	Leu	Gly	Lys	Lys	Ala	Pro	Ile	Ser	Leu	Arg	Val	Asn	Pro	
				140		•			145					150			
			gat														1254
	Asn	Val	Asp	Ala	Lys	Thr	His		Tyr	Ile	Ser	His		Ala	Leu	Lys	
35	000	aat	155	111				160		4			165				
			aaa														1302
	voii	170	Lys	rne	GIY	Val	175	rne	GIU	ASP	AIA		Gly	Leu	Туг	Glu	
40	222		gcg	caa	cta	cca		atc	g a g	at a	000	180	at a	<b>~~</b> +	<b>.</b>		1050
			Ala														1350
	185				204	190			<b>01</b> 0	141	195	013	101	voh	cys	200	
45		ggc	tcg	caa	atc	act	gag	cte	tca	cct		 ctc	gat	ጀቦቦ	tto		1398
			Ser														1550
		•	, .		205					210					215	пор	
50	aaa	gta	ttg	ggc	ctg	gta	gat	gca	ttg	gcc	gcc	aaa	ggc	att		atc	1446
50	Lys																
				220		,			<b>2</b> 25					230		-	
	cag																1494
55			He														

			235					240					245				
		cca															1542
5	Thr	Pro	Pro	Asp	Phe	Ala	Ala	Tyr	Thr	Ala	Ala	lle	Leu	Lys	Lys	Leu	
		250					255		•			260					
		ggc															1590
10		Gly	Arg	Asn	Val		Val	Leu	Phe	Glu		Gly	Arg	Ala	Leu	Val	
	265					270					275					280	
		aac															1638
15	GIY	Asn	Ala	GIY	285	Leu	reu	ınr	Lys	290	GĻU	Tyr	Leu	Lys		Gly	
	gaa	acc	222	aac		geg	att	øtc	σať		acc	a tor	200	<b>"</b> "	295		1000
		Thr															1686
20			-, -	300				,	305	****	114	1100	17311	310	ned	Me C	
20	cgc	ccg	gct	ttg	tat	gat	gct	ttc	cac	aac	att	acg	acc		gcc	act	1734
		Pro															
			315					320					325				
25		gca															1782
	Ser	Ala	Ala	Pro	Ala	Gln		Tyr	Glu	He	Val		Pro	Val	Cys	Glu	
	4	330			44.		335					340					
30		ggt															1830
	345	Gly	voh	Lile	Leu	350	пта	ASP	Arg	ınr	355	Ala	116	GIU	Glu		
		tac	ctg	gcg	att		tcc	gca	ggc.	get		PPC	atø	age	ator	360	1878
<b>35</b> .		Tyr													_	_	1010
	-				365				. •	370	-,-	•		•••	375		
	agc	aac	tac	aac	acg	cgc	gcc	cgt.	gcc	gca	gag	gta	ttg	gtt	gat	ggt	1926
40	Ser	Asn	Tyr	Asn	Thr	Arg	Ala	Arg	Ala	Ala	Glu	Val	Leu	Val	Asp	Gly	
			•	380					385					390			
	gac	cag	gtg	cat	gtg	atc	cgt	gaa	cgt	gaa	caa	att	gcc	gac	ctg	ttt	1974
45	Asp	Gln		HIS	Val	He			Arg	Glu	Gln			Asp	Leu	Phe	
	200		395	ogt.		~+ <i>~</i>		400 +	. 44				405	1			
		ctg Leu						laac	attg	ac g	gcaa	cccc	t aa	taaa	aaaa	•	2025
50		410	Old	VI P	1111		415										
			gc c	aago	ttce			atta	ata	gcer	at.c	cttt	aatr	22 2	oat n	acggt	2085
																agcac	
56																gaaat	
55																tgact	
													-			-	

5	aaa atc aat aat	atgo aato aaao tagto	tggc tggt cagg gaaa	agga gaca gcaa	aatga agaat aactg	egt p tot p sot p	ggtgg gcatg gngco	gtgaa gtaga etcta	at gi	ttgat gccag tctgo	taati gcaca cctta	c cgc a ato g gtt	tgag aggt tacc	gat caa ttg	acce tcti gtca	cgccgat gtgcgac tgtgttg atcggta ctaaagc	2385 2445 2505
15	<21 <21	.0> 1 .1> 4 .2> F .3> M	115	loph	i l'us	met	hylo	trop	hus `								
20		0> 1 Thr		Phe	Ser 5	Ile	Gln	Gln	Gly	Leu 10		His	Ala	Glu	Asn 15	Val	÷
25				20					25	Gln	Thr			30	Val	Tyr Leu	
30	Thr	Gly 50	35 His	Asp	His	Leu	I le 55	40 Cys	Phe	Ala	Val	Lys 60	45 Ala	Asn	Pro	Ser	·
35	65		Ile Gly		Glu	70				Leu	75				Asp	80	
40			Val Leu	100					105					110			
45			115 Asp					120					125				
	Pro 145	Ile	Ser	Leu	Arg	Val 150		Pro	Asn	Val	Asp 155		Lys	Thr	His	Pro 160	
			Ser		165					170					175		
55			Ala His	180					185					190			

	195 200 205	
	Ser Pro Phe Leu Asp Ala Leu Asp Lys Val Leu Gly Leu Val Asp Ala	
5	210 215 220 Leu Ala Ala Lys Gly Ile His Ile Gln His Ile Asp Val Gly Gly	
	225 230 235 240	
	Val Gly lie Thr Tyr Ser Asp Glu Thr Pro Pro Asp Phe Ala Ala Tyr	
10	245 250 255	
	Thr Ala Ala Ile Leu Lys Lys Leu Ala Gly Arg Asn Val Lys Val Leu 260 265 270	
15	Phe Glu Pro Gly Arg Ala Leu Val Gly Asn Ala Gly Val Leu Leu Thr 275 280 285	
	Lys Val Glu Tyr Leu Lys Pro Gly Glu Thr Lys Asn Phe Ala Ile Val 290 295 300	
20	Asp Ala Ala Met Asn Asp Leu Met Arg Pro Ala Leu Tyr Asp Ala Phe 305 310 315 320	
	His Asn Ile Thr Thr Ile Ala Thr Ser Ala Ala Pro Ala Gln Ile Tyr	
25	325 330 335	
	Glu Ile Val Gly Pro Val Cys Glu Ser Gly Asp Phe Leu Gly His Asp 340 345 350	
30	Arg Thr Leu Ala Ile Glu Glu Gly Asp Tyr Leu Ala Ile His Ser Ala 355 360 365	
	Gly Ala Tyr Gly Met Ser Met Ala Ser Asn Tyr Asn Thr Arg Ala Arg 370 375 380	
35	Ala Ala Glu Val Leu Val Asp Gly Asp Gln Val His Val Ile Arg Glu	
	385 390 395 400	
	Arg Glu Gln Ile Ala Asp Leu Phe Lys Leu Glu Arg Thr Leu Pro	
40	405 410 415	
	<210> 15	
	<211> 39	
15	<212> DNA	
	<213> Artificial Sequence	
•	<220>	
50	<223> primer for amilification of tac promoter	
	<400> 15	
5	agggaattee eegttetgga taatgttttt tgegeegae 39	9

	<210> 16	
	<211> 58	
5	<212> DNA	
	<213> Artificial Sequence	
10	<220>	
	<223> primer for amilification of tac promoter	
	<400> 16	
15	cggatgcatc tagagttaac ctgcagggtg aaattgttat ccgctcacaa ttccacac	58
	<210> 17	
20	<211> 35	
	<212> DNA	
	<213> Artificial Sequence	
25	<220>	
	<223> primer for amilification of dapA*24 gene	
30	<400> 17	
	tgacctgcag gtttgcacag aggatggccc atgtt	.35
35	<210> 18	
	<211> 36	
	<212> DNA	
10	<213> Artificial Sequence	
	<220>	
•	<223> primer for amilification of dapA*24 gene	
15		
	<400> 18	
	cattetagat cectaaactt tacagcaaac eggeat	36
io	<210> 19	
	<211> 35	
	<211> 35 <212> DNA	
5	2212 Antificial Company	

<220> <223> primer for amilification of lysC*80 gene <400> 19 gaacctgcag gccctgacac gaggtagatt atgtc 35 10 <210> 20 <211> 55 <212> DNA 15 <213> Artificial Sequence <220> 20 <223> primer for amilification of lysC*80 gene <400> 20 25 ctttcggcta gaagagcgag atgcagataa aaaaattaaa ggcaattatt ctccg 55

### 30 Claims

50

- 1. A Methylophilus bacterium having L-amino acid-producing ability.
- 2. The *Methylophilus* bacterium according to claim 1, wherein the L-amino acid is L-lysine, L-valine, L-leucine, L-isoleucine or L-threonine.
  - 3. The Methylophilus bacterium according to claim 1, which shows resistance to an L-amino acid analogue or L-amino acid auxotrophy.
- . 40 4. The Methylophilus bacterium according to claim 1, wherein L-amino acid biosynthetic enzyme activity is enhanced.
  - 5. The *Methylophilus* bacterium according to claim 1, wherein dihydrodipicolinate synthase activity and aspartokinase activity are enhanced, and the bacterium has L-lysine-producing ability.
- 45 **6.** The *Methylophilus* bacterium according to claim 1, wherein dihydrodipicolinate synthase activity is enhanced, and the bacterium has L-lysine-producing ability.
  - The Methylophilus bacterium according to claim 1, wherein aspartokinase activity is enhanced, and the bacterium has L-lysine-producing ability.
  - 8. The *Methylophilus* bacterium according to any one of claims 5 to 7, wherein an activity or activities of one, two or three of enzymes selected from aspartic acid semialdehyde dehydrogenase, dihydrodipicolinate reductase and diaminopimelate decarboxylase is/are enhanced.
- 55 9. The Methylophilus bacterium according to claim 5, wherein the dihydrodipicolinate synthase activity and the aspartokinase activity are enhanced by transformation through introduction into cells, of a DNA coding for dihydrodipicolinate synthase that does not suffer feedback inhibition by L-lysine and a DNA coding for aspartokinase that does not suffer feedback inhibition by L-lysine.

This Page Blank (uspto)

- 10. The Methylophilus bacterium according to claim 1, wherein activities of aspartokinase, homoserine dehydrogenase, homoserine kinase and threonine synthase are enhanced, and the bacterium has L-threonine-producing ability.
- 11. The bacterium according to any one of claims 1 to 10, wherein the Methylophilus bacterium is Methylophilus methylotrophus.
- 12. A method for producing an L-amino acid, which comprises culturing a Methylophilus bacterium as defined in any one of claim 1 to 11 in a medium to produce and accumulate an L-amino acid in culture and collecting the L-amino acid from the culture.
  - 13. The method according to claim 12, wherein the medium contains methanol as a main carbon source.
- 14. A method for producing bacterial cells of a Methylophilus bacterium with an increased content of an L-amino acid, which comprises culturing a Methylophilus bacterium as defined in any one of claim 1 to 11 in a medium to produce and accumulate an L-amino acid in bacterial cells of the bacterium.
  - 15. The method for producing bacterial cells of the *Methylophilus* bacterium according to claim 14, wherein the L-amino acid is L-lysine, L-valine, L-leucine, L-isoleucine or L-threonine.
  - 16. A DNA which codes for a protein defined in the following (A) or (B):

20

25

30

40

45

55

- (A) a protein which has the amino acid sequence of SEQ ID NO: 6, or
- (B) a protein which has an amino acid sequences of SEQ ID NO: 6 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has aspartokinase activity.
- 17. The DNA according to claim 16, which is a DNA defined in the following (a) or (b):
  - (a) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 510 to 1736 of SEQ ID NO: 5; or
  - (b) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 510 to 1736 of SEQ ID NO: 5 or a part thereof under a stringent condition, and codes for a protein having aspartokinase activity.
- 18. A DNA which codes for a protein defined in the following (C) or (D):
  - (C) a protein which has the amino acid sequence of SEQ ID NO: 8, or
  - (D) a protein which has an amino acid sequences of SEQ ID NO: 8 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has aspartic acid semialdehyde dehydrogenase activity.
  - 19. The DNA according to claim 18, which is a DNA defined in the following (c) or (d):
    - (c) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 98 to 1207 of SEQ ID NO: 7; or
    - (d) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 98 to 1207 of SEQ ID NO: 7 or a part thereof under a stringent condition, and codes for a protein having aspartic acid semialdehyde dehydrogenase activity.
- 20. A DNA which codes for a protein defined in the following (E) or (F):
  - (E) a protein which has the amino acid sequence of SEQ ID NO: 10, or
  - (F) a protein which has an amino acid sequences of SEQ ID NO: 10 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has dihydrodipicolinate synthase activity.
  - 21. The DNA according to claim 20, which is a DNA defined in the following (e) or (f):
    - (e) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers

1268 to 2155 of SEQ ID NO: 9; or

5

10

15

25

30

35

40

45

50

55

(f) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 1268 to 2155 of SEQ ID NO: 9 or a part thereof under a stringent condition, and codes for a protein having dihydrodipicolinate synthase activity.

- 22. A DNA which codes for a protein defined in the following (G) or (H):
  - (G) a protein which has the amino acid sequence of SEQ ID NO: 12, or
  - (H) a protein which has an amino acid sequences of SEQ ID NO: 12 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has dihydrodipicolinate reductase activity.
- 23. The DNA according to claim 22, which is a DNA defined in the following (g) or (h):
- (g) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 2080 to 2883 of SEQ ID NO: 11; or
  - (h) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 2080 to 2883 of SEQ ID NO: 11 or a part thereof under a stringent condition, and codes for a protein having dihydrodipicolinate reductase activity.
- 20 24. A DNA which codes for a protein defined in the following (I) or (J):
  - (I) a protein which has the amino acid sequence of SEQ ID NO: 14, or
  - (J) a protein which has an amino acid sequences of SEQ ID NO: 14 including substitution, deletion, insertion, addition or inversion of one or several amino acids, and has diaminopimelate decarboxylase activity.
  - 25. The DNA according to claim 24, which is a DNA defined in the following (i) or (j):
    - (i) a DNA which has a nucleotide sequence comprising the nucleotide sequence of the nucleotide numbers 751 to 1995 of SEQ ID NO: 13; or
    - (j) a DNA which is hybridizable with a probe having the nucleotide sequence of the nucleotide numbers 751 to 1995 of SEQ ID NO: 13 or a part thereof under a stringent condition, and codes for a protein having diaminopimelate decarboxylase activity.




FIG. 1





FIG. 2








FIG. 4




FIG. 5




FIG. 6




FIG. 7

#### INTERNATIONAL SEARCH REPORT International application No. PCT/JP00/02295 CLASSIFICATION OF SUBJECT MATTER Int.Cl7 C12N1/21, 1/32, 9/00, 15/52, C12P13/04 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Cl2N1/20-1/21, 9/00-9/99, 15/52-15/61, Int.Cl C12P13/04-13/14 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) GenBank/EMBL/DDBJ/GeneSeq, SwissProt/PIR/GeneSeq. WPI (DIALOG), BIOSIS (DIALOG) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP, 35831, A2 (IMPERIAL CHEMICAL INDUSTRIES LIMITED), 1.4.11-14 16 September, 1981 (16.09.81) & NO, 8100773, A & DK, 8100952, A & JP, 56-140893, A & PT, 72630, A & CA, 1187011, A & DE, 3173415, G & CA, 1187011, A & RO, 92662, A x WINDASS, J. D. et al., "Improved conversion of methanol 1.4.11-14 to single-cell protein by Methylophilus methylotrophus", Nature, October 2, 1980, Volume 287, pp. 396-401 SCHENDEL, Frederick J. et al., "Cloning and Nucleotide 17 Sequence of the Gene Coding for Aspartokinase II from a Thermophilic Methylotrophic Bacillus sp. ", Applied and En- vironmental Microbiology, September 1992, Volume 58, Number 9, pages 2806-2814 GenBank Accession No. M93419 HOANG, Tung T. et al., "Molecular genetic analysis of the х 19 region containing the essential Pseudomonas aeruginosa asd gene encoding aspartate-β-semialdehyde Further documents are listed in the continuation of Box C. See patent family annex. Special categories of cited documents later document published after the international filing date or document defining the general state of the art which is not considered to be of particular relevance earlier document but published on or after the international filling priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive document which may throw doubts on priority claim(s) or which is step when the document is taken alone document of particular relevance; the claimed invention cannot be cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document published prior to the international filing date but later document member of the same patent family than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report 05 July, 2000 (05.07.00) 18 July, 2000 (18.07.00) Name and mailing address of the ISA/ Authorized officer

Japanese Patent Office

Form PCT/ISA/210 (second sheet) (July 1992)

Facsimile No.

Telephone No.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/02295

ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
	dehydrogenase", Microbiology, March 1997, Volume	TOTAL TO COME NO
x	143, Part 3, pp. 899-907 GenBank Accession No.Ull055 YAMAMOTO, Yoshihiro et al., "Construction of a Contiguous 874-kb Sequence of the Escherichia coli-K12 Genome corresponding to 50.5-68.8 min on the Linkage Map and Analysis of Its Sequence Features", DNA Research, April 28, 1997 Volume 4, Number 2, pp.91-113	
x	GenBank Accession No. D90877  BONNASSIB, S. et al., "Nucleotide sequence of the dapper from Corynebacterium glutamicum", Nucleic Acide Research, November 11, 1990, Volume 18, Number 21, page 6421  GenBank Accession No.X53993	, 1
х	BOUVIER, J. et al., "Nucleotide Sequence and Expression of the Escherichia coli dapB Gene", The Journal of Biological Chemistry, December 10, 1984, Volume 259, Number 23, pp.14829-14834 GenBank Accession No. M10611	: ]
x .	DEKKERS, Linda C. et al., "A site-specific recombinase is required for competitive root colonization by Pseudomonas fluorescens WCS365", Proceedings of the National Academy of Sciences, USA, June 9, 1998, Volume 95, Number 12, pp.7051-7056 GenBank Accession No.Y12268	
A	EP, 37273, A2 (IMPERIAL CHEMICAL INDUSTRIES LIMITED), 07 October, 1981 (07.10.81) & BR, 8101907, A & DK, 8101404, A & JP, 57-8782, A & ZA, 8102086, A & CA, 1187012, A & IL, 62514, A & DE, 3175828, G & KR, 8701127, B	1-25
	WO, 96/41871, A1 (Ajinomoto Co., Inc.) 27 December, 1996 (27.12.96) & EP, 834559, A1 & SK, 9701705, A3 & CN, 1203629, A & HU, 9900149, A2 & US, 5989875, A & MX, 9710044, A1	1-25
].	Kerney, P. et al., "Regulation and routes of biosynthesis of serine and arginine in Methylophilus methylotrophus ASI", FEMS Microbiology Letters, July 1987, Volume 42, Nos.2-3, pp. 109- 112	1-25
A	JP, 1-235595, A (Kyowa Hakko Kogyo Co. Ltd.) 20 September, 1989 (20.09.89) (Family: none)	.1-25
	JP, 53-34987, A (Yoshiki Tani) 31 March, 1978 (31.03.78)	1-25

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP00/02295

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: because they relate to subject matter not required to be searched by this Authority, namely: 2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: The requirement of unity of invention in international application (PCT Rule 13.1) is not satisfied unless there is a technical relationship in a group of inventions involving one or more of the same or corresponding technical features. The term "technical feature" means a technical feature clearly showing the contribution to the prior art by the inventions as set forth in claims as a whole (PCT Rule 13.2). The requirement of unity of invention is judged without considering whether a group of inventions are described in separate claims or in a single claim in an alternative form (PCT Rule 13.3). As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: The additional search fees were accompanied by the applicant's protest. Remark on Protest No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

#### INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/02295

### Continuation of Box No. II of continuation of first sheet (1)

Inventions as set forth in claims 1 to 25 have a matter in common of a "bacterium belonging to the genus Methylophilus and having an L-amino acid productivity". However, document 1 (Japanese Patent Laid-Open No. 140893/1981) and document 2 (Nature, 287(5781), 396-401 (1980)) describe a bacterium belonging to the genus Methylophilus and carrying Escherichia coli-origin glutamate dehydrogenase (GDH) gene transferred in a state of allowing the expression thereof. Furthermore, a process for producing an amino acid by culturing this bacterium is stated in document 1 (see, for example, claim 19 and thereafter). As also stated in the description (p. 13) of the present international application, GDH gene is a gene imparting an L-glutamic acid productivity to a bacterium belonging to the genus Methylophilus. Therefore, it can be said that the bacterium belonging to the genus Methylophilus as described in document 1 or document 2 is a "bacterium belonging to the genus Methylophilus and having an L-glutamic acid productivity". Accordingly, there had been publicly known a bacterium belonging to the genus Methylophilus and having a productivity of 1-glutamic acid, i.e., one of L-amino acids. Thus, the "bacterium belonging to the genus Methylophilus and having an L-amino acid productivity" which is the matter common to inventions as set forth in claims 1 to 25 cannot be regarded as a "special technical feature" as defined in PCT Rule 13.2.

Also, there had been publicly known a dihydrodipicolinate synthase gene (i.e., a gene capable of imparting an L-lysine productivity to a bacterium belonging to the genus Methylophilus) originating in a bacterium belonging to the genus Corynebacterium (see, for example, document 3 (Nucleic Acids Res., 18(21), 6421 (1990)). Accordingly, the "special technical feature" common to inventions as set forth in claims 16 to 25 is not an "enzyme gene being usable in enhancing the L-lysine productivity of a bacterium belonging to the genus Methylophilus" but an "enzyme gene originating in a bacterium belonging to the genus Methylophilus and being usable in enhancing the L-lysine productivity of a bacterium belonging to the genus Methylophilus". Thus, it may be said that there is no "special technical feature" as defined in PCT Rule 13.2 between the group of inventions as set forth in claims 1 to 15 relating to a bacterium belonging to the genus Methylophilus and having an L-lysine productivity and the group of inventions as set forth in claims 16 to 25.

Such being the case, the claims involve the following six groups of inventions:

- ① inventions relating to abacterium belonging to the genus Methylophilus and having an L-lysine productivity as set forth in claims 1 to 15:
- ② inventions relating to a bacterium belonging to the genus Methylophilus and having an L-valine productivity as set forth in claims 1 to 15;
- ③ inventions relating to a bacterium belonging to the genus Methylophilus and having an L-leucine productivity as set forth in claims 1 to 15;
- (5) inventions relating to a bacterium belonging to the genus Methylophilus and having an L-threonine productivity as set forth in claims 1 to 15; and
  - 6 inventions as set forth in claims 16 to 25.

Form PCT/ISA/210 (extra sheet) (July 1992)